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SUMMARY 
Microgels, also referred to as nanogels, are hydrophilic polymer networks 
synthesized into micro- or nano-sized hydrogel particles. Due to their relative ease of 
synthesis and highly tunable properties, they have been explored extensively for a range of 
biomedical applications, including therapeutic delivery, imaging, and biosensors. Yet 
despite decades of research, only a handful of microgel-based technologies have reached 
clinical trials. Primary barriers to clinical translation of microgels include rapid clearance 
from circulation and toxicity or off-target effects. While there have been many 
advancements in microgel research, there still exists a lack of understanding of the factors 
that drive microgel behavior in vivo 
 To address this gap in knowledge, this work uses poly(N-isopropylacrylamide)-co-
acrylic acid (pNIPAM-AAc) microgels as a case study in how microgel crosslink density 
affects mechanical properties of microgels in physiologic settings, and correspondingly 
influences their behavior in vivo. The central hypothesis of this work is that increased 
crosslinking leads to shorter blood circulation time of microgels, and enhanced margination 
to the walls of blood vessels. Microgel characteristics were evaluated with a combination 
of single microgel atomic force microscopy (AFM) nanoindentation techniques along with 
light scattering and rheological analysis of microgel suspensions. A variety of microfluidic 
systems were used to investigate microgel behavior in whole blood, while in vivo testing 
was carried out to determine biodistribution, clearance time, and potential toxicity.  
 Increased crosslinking had minimal effect on clearance time and margination of 
pNIPAM-AAc microgels, though crosslinking was associated with longer retention time 
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in the kidneys. During biodistribution studies, it was observed that some mice who received 
crosslinked microgels showed signs of significant toxicity. Follow-up in vitro and in vivo 
studies revealed that crosslinked microgels have a greater tendency to form large 
aggregates in blood that can occlude lung microvasculature, though this does not lead to 
an overall inflammatory response. Instead, it is likely that crosslinked microgels 
occasionally form especially large aggregates that result in rare catastrophic events similar 
to a pulmonary embolism. Further exploration of this phenomenon revealed that aggregate 
formation is driven by hydrophobic interactions and exacerbated by the binding of plasma 
proteins such as albumin. Rational design of microgel-based therapies should utilize stably 
hydrophilic polymers to minimize protein binding and reduce the risk of aggregate 






CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
Microgels, also known as nanogels, are deformable microparticles consisting of 
crosslinked networks of hydrophilic polymers. Due to their relative ease of synthesis and 
tunable features, including size, charge, stiffness, porosity, hydrophobicity, and 
degradation, microgels are an attractive platform for therapeutic drug delivery, imaging 
contrast agents, and biosensors. Yet despite a wide breadth of applications explored in 
published literature over the past two decades, only a couple of therapies involving 
microgels have reached clinical trials. The primary barriers to clinical translation of 
microgel-based therapies are rapid clearance in vivo and microgel associated toxicity or 
off-target effects. While there is plenty of research describing potential biological uses of 
microgels, there exists a critical gap in knowledge about the long-term safety of microgel 
therapies. 
 This work aims to fill that gap by using a standard microgel design as a case study. 
Poly(N-isopropylacrylamide) (pNIPAM) is one of the most commonly used polymers for 
microgel design, in part because of its unique stimuli-responsive behaviors. pNIPAM-
based microgels have been synthesized with a wide range of crosslinking density using the 
common crosslinker N,N’-methylenebisacrylamide (BIS), resulting in varying stiffness in 
the final product. Additionally, pNIPAM microgels are frequently co-polymerized with 
acrylic acid (AAc), which adds a net negative charge and allows for simple protein ligation. 
But the effect of these modifications on microgel behavior in vivo is poorly characterized. 
The central question of this research is: 
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How does crosslink density influence the clearance time, biodistribution, and safety 
of pNIPAM-AAc microgels? 
This question was addressed through two specific aims: 
Aim 1: Determine the effect of pNIPAM-AAc crosslinking on mechanical behaviors 
of microgels in biologic fluids 
 The central hypothesis of this aim was that increased crosslinking of microgels 
would result in stiffer individual microgels, and that exposure to plasma would further 
increase the Young’s modulus of microgels through the formation of a protein corona. 
Furthermore, I hypothesized that the increased Young’s modulus of crosslinked microgels 
would result in enhanced margination in whole blood and higher apparent blood viscosity. 
These hypotheses were interrogated with atomic force microscopy (AFM) 
nanoindentation, dynamic light scattering (DLS), and microfluidic imaging of microgels 
in whole blood. 
Aim 2: Establish a relationship between microgel crosslink density, aggregate 
formation, and pulmonary toxicity 
 The central hypothesis of this aim was that BIS-crosslinked microgels more readily 
form aggregates in blood, and that these aggregates become trapped in lung 
microvasculature, leading to endothelial damage and inflammation. Aggregate formation 
in a variety of solvents was tested using confocal microscopy, and evaluation of occlusion 
and toxicity was investigated in both in vitro microfluidic devices and in vivo mouse 
models with histology, flow cytometry, and cytokine quantification. 
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Broader Impacts: 
 Although these aims are focused on pNIPAM-AAc microgels, this thesis discusses 
how the results presented here can be applied to the rational design of a variety of microgel 
formulations. Understanding the microgel characteristics that lead to aggregation in vivo 
will help to avoid toxicity in preclinical trials and accelerate microgel-based therapies to 
the clinical space. Furthermore, the finding that microgels naturally accumulate in the lungs 
and kidneys present a unique opportunity for targeted therapeutic delivery without the need 
for ligation of targeting moieties. 
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CHAPTER 2. BACKGROUND INFORMATION 
2.1 Properties of Microgels 
2.1.1 What is a Microgel? 
Microgels, also known as nanogels, are formed by synthesizing crosslinked 
hydrophilic polymer networks into micro- or nano-sized hydrogel particles. Microgels are 
distinguished from other nanoparticles by their ability to swell with a high volume of water 
relative to their total size, unlike metallic nanoparticles (e.g. gold, silver) or rigid 
polystyrene nanoparticles. Microgels can be synthesized from a variety of hydrophilic 
polymers, such as pNIPAM, PEG, poly(methyl acrylate) (PMA), and polyethylenimine 
(PEI), to name a few (1). pNIPAM-based microgels in particular have been extensively 
studied over the past several decades due to the relative ease of synthesis and ability to 
modulate size, charge, porosity, hydrophobicity, stimuli-responsiveness, and degradation 
kinetics through changes in reaction conditions (2). Microgels are mostly spherical 
particles, though recent advancements have demonstrated the fabrication of microgel 
materials of varying shapes (3, 4). Often, microgels are synthesized with a core-shell 
structure with a hydrogel “shell” surrounding a “core” that could be comprised of either 
another hydrogel or a different material (2), though other synthesis strategies have yielded 
microgels with hollow cores (5).  
 In addition to their biological applications, described in section 2.3, microgels have 
been explored for a variety of research and industrial purposes, including rheology 
modifiers (6, 7), photonic crystals (8-12), and responsive membrane design (13). 
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Researchers have utilized the high tunability and responsiveness of microgels to fit the 
needs of each application. 
2.1.1.1 Crosslinking of pNIPAM Microgels 
pNIPAM microgels are synthesized by a process known as “precipitation 
polymerization” whereby a sulfate radical initiates NIPAM monomers, which polymerize 
into progressively longer chains until they collapse into a colloidally unstable “precursor 
particle.” These precursor particles then aggregate until they form a colloidally stable 
particle high above the lower critical solution temperature (LCST) (14). In order for any 
microgel to maintain its shape and stability in the context of other materials, individual 
polymer chains must be crosslinked together to form a network. Most commonly, this is 
accomplished by the addition of a chemical crosslinker during synthesis reactions, resulting 
in covalent bonds between polymer chains (15). However, crosslinking without a chemical 
crosslinker is possible, by utilizing hydrogen binding, hydrophobic interactions, or 
electrostatic properties of polymer chains (16, 17).  
 
Figure 1: pNIPAM (left) and its crosslinker BIS (right). Images adapted from Wikipedia 
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N,N’-Methylenebisacrylamide (BIS) is widely used as an exogenous crosslinker for 
acrylamide-based microgels such as pNIPAM (Figure 1). pNIPAM microgels can also be 
synthesized in a crosslinker-free reaction, which utilizes the capacity of pNIPAM chains 
to undergo chain transfer reactions at temperatures high above the LCST of NIPAM, 
resulting in self-crosslinked networks. pNIPAM microgels synthesized without an 
exogenous crosslinker (often referred to as “ultra-low crosslinked” or ULC) are similar to 
BIS-crosslinked microgels in most characteristics including size and shape, though they 
display lower solid content and higher swelling ratios than BIS-crosslinked microgels (16). 
ULC microgels can be fabricated with a variety of sizes, swelling ratios, and solid content 
by varying the temperature of the synthesis reaction, amount of NIPAM monomer, and 
concentration of the free-radical initiator (18). While both ULC and BIS-crosslinked 
microgels typically display diameters of approximately 1 m in their swollen state, Lyon 
et al. have generated so-called “giant” ULC microgels with diameters of about 8 m by 
initiating synthesis at 45 ˚C and increasing to 60 ˚C at a rate of 30 ˚C/hour (19). 
2.1.2 Swelling Behavior of Thermoresponsive pNIPAM Microgels 
At low temperatures, pNIPAM chains interact with water molecules primarily 
through hydrogen binding with the amide side groups of NIPAM. As temperature increases 
past the lower critical solution temperature (LCST), hydrogen bonding weakens, and 
hydrophobic polymer-polymer interactions (driven by the isopropyl groups of NIPAM) are 
favored. The net result of these changes is the shift in pNIPAM chain structure from 
random coil to collapsed globule. When this phase transition occurs over the entirety of the 
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polymer network comprising a microgel, water is expelled as the microgel collapses (2).  
This is commonly referred to as the volume phase transition temperature (VPTT). 
 The LCST of pNIPAM in water is ~32 ˚C, but this can be modulated by changing 
synthesis parameters or solution components. For example, acrylic acid (AAc) is often co-
polymerized into pNIPAM networks to introduce carboxylic acid moieties than can be used 
for ligation of small molecules or proteins. AAc also gives pNIPAM microgels a net 
negative charge at neutral or high pH. Under these conditions, intraparticle electrostatic 
repulsions prevent the collapse of pNIPAM chains and stabilize the swollen conformation, 
effectively raising the LCST. This effect can be reversed by lowering the pH of the solvent 
to below the pKa of AAc, or by adding a source of cations (such as NaCl or Ca2+) to shield 
negative charges from repelling one another. Additionally, increased osmotic pressure 
from solvated ions contributes to enhanced deswelling of microgels (2, 20). Furthermore, 
the degree of crosslinking can influence swelling behavior of pNIPAM microgels. Gao and 
Frisken showed that ULC microgels display a greater swelling ratio (measure of the 
difference between swollen diameter and collapsed diameter) than BIS-crosslinked 
microgels (16).  
 Swelling behavior is an important consideration when designing microgel-based 
technologies. Any biological application of microgels should take into account 
physiological conditions; not only is body temperature (37 ˚C) very close to the LCST of 
pNIPAM, but biological fluids are replete with salts, divalent cations such as calcium, and 
charged proteins that may influence swelling behavior. Collapsed microgels occupy a 
much smaller space than swollen ones, reducing their effective volume fraction within a 
given medium and affecting the intended use of the microgels. 
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2.1.3 Mechanical Properties of pNIPAM Microgels 
Microgels are generally thought of as soft materials. Due to their relatively low 
solid content and random coil polymer chain structure, they are far more deformable than 
particles formed from non-hydrogel polymers such as polystyrene, or other material classes 
like metals and ceramics. Additionally, because the majority of a microgel’s volume is 
comprised of the water held in its polymer network, which is expelled upon the application 
of force, they are classified as viscoelastic solids; i.e., their mechanical responses are time-
dependent. Nonetheless, several groups have attempted to characterize the ensemble 
behavior of microgel suspensions, as well as the equilibrium mechanical properties of 
individual microgels.  
 Atomic force microscopy (AFM) nanoindentation allows for precise sampling of 
the mechanical properties of materials. Typically, AFM probes for imaging purposes are 
designed with a sharp, pyramidal tip with a radius of ~50 nm to grant high spatial 
resolution. However, these tips result in high stress on the material, often causing plastic 
deformation in otherwise elastic materials. For this reason, AFM tips for sampling soft 
materials are often modified by adding a large colloidal probe (e.g. a polystyrene bead with 
diameter 1-5 m) to the end of the cantilever. Using this method, Hashmi and Dufresne 
measured the elastic (Young’s) modulus of pNIPAM particles crosslinked with 3.5 mol% 
BIS throughout the phase transition. Microgels fully swollen in water at 27 ˚C displayed a 
Young’s modulus of 13 kPa, whereas microgels past the LCST had stiffened almost an 
order of magnitude, to 123 kPa (21). Interestingly, there is a noted discrepancy in literature 
values for the modulus of pNIPAM microgels, even when using similar methodology. 
Using AFM nanoindentation as well, Tagit et al. reported in 2008 that pNIPAM microgels 
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crosslinked with 6.8 mol% BIS below the LCST had a Young’s modulus of 1.8 ± 0.2 MPa, 
and stiffened to 12.8 ± 3.6 MPa after the phase transition past the LCST (22).  While the 
relative difference between swollen and collapsed measurements is similar for the two 
studies, the absolute modulus measurements differ by two orders of magnitude; far more 
than could be expected to result from experimental error or the differences in crosslink 
density.  
 Obviously, the degree of crosslinking would be expected to influence microgel 
stiffness. ULC microgels are the least crosslinked pNIPAM microgels, and were measured 
by Bachman et al. using AFM nanoindentation to have an elastic modulus of approximately 
10 kPa (23).  When the same group crosslinked PEI microgels with 4% BIS, the modulus 
increased by an order of magnitude to about 100 kPa, though these measurements were 
performed on microgel films, not single microgels (24). Notably, all of these measurements 
to date have been done in simple solvents such as water or saline. To understand the 
mechanics of microgels used for biological applications, AFM measurements should 
measure how stiffness changes after microgels are exposed to protein-rich biological fluids. 
 It is worthwhile to ask why changes in microgel stiffness could affect biological 
outcomes of microgel-based technologies. Cells are uniquely sensitive to the stiffness of 
their underlying substrate, with differential stiffness driving simple cell behaviors such as 
motility and proliferation, as well as coordinated events such as differentiation and tissue 
morphogenesis (25-27). Furthermore, there is increasing evidence that the stiffness of 
micro- and nanoparticles regulates the manner by which they are taken up by immune cells 
such as macrophages. Banquy et al. found that nanoparticles with a Young’s modulus of 
~18 kPa were taken up by macropinocytosis, whereas stiffer particles (~200 kPa) were 
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internalized via clathrin-mediated endocytosis (28). Additionally, Merkel et al. have 
demonstrated that by decreasing the modulus of a red blood cell-mimicking hydrogel by 
8-fold, a 30-fold increase in circulation time could be achieved (29). For these reasons, the 
mechanical properties of microgels are an important design parameter to direct in vivo 
outcomes such as clearance time, biodistribution, and immune response. 
2.2 The Protein Corona and its Influence on Biological Outcomes 
Any material that comes into contact with physiological fluids is subject to fouling 
by proteins, and micro/nanoparticles are no exception. Upon intravenous injection, plasma 
proteins interact with the surface of the particle, adsorbing through non-covalent binding 
such as hydrophobicity, charge, hydrogen binding, and van der Waals forces. The resulting 
layer of proteins is referred to as a protein “corona,” and its composition is dynamic. 
Initially, a “soft” corona of weakly bound proteins surrounds the particle, which over time 
is replaced by higher-affinity proteins that form a “hard” corona on the surface of the 
particle (Figure 2). For many micro/nanoparticles, the corona is largely comprised of 
albumin, the most abundant serum protein. However, less common proteins such as 
fibrinogen, plasminogen, immunoglobulins, and apolipoproteins have been identified in 
protein coronae, sometimes in greater amounts than their proportional concentration in 
serum would suggest (30). 
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Figure 2: Example of protein corona formation on a nanoparticle surface. Protein 
adsorption is dynamic and dependent on the affinity of individual proteins to the 
nanoparticle surface as well as other proteins. Figure from Fleischer and Payne, 2014 (30).   
2.2.1 The Role of the Protein Corona in Determining In Vivo Fate 
The behavior of micro/nanoparticles in blood circulation is a critical determinant 
of their efficacy and safety. As with any biomaterial, micro/nanoparticles are recognized 
by the body’s immune system as foreign objects, and are typically taken up by the 
mononuclear phagocyte system (MPS, consisting of dendritic cells, blood monocytes, and 
macrophages) following injection. In addition to reducing the effective dose of particles in 
circulation, MPS uptake is correlated with enhanced inflammation and toxicity (31, 32). 
 Cells interact with biomaterials through the proteins bound to their surface before 
they encounter the material itself. Adsorbed proteins bind receptors (e.g. Mac-1) on the 
surface of phagocytic cells that regulate particle binding and internalization (33-36). Both 
quantitative and qualitative changes in the protein corona can influence their interactions 
with the MPS. In general, more bound protein of any type leads to greater immune cell 
binding and particle internalization, reducing the effective dose and half-life of 
nanoparticles in circulation (37, 38). However, recent work has demonstrated that the 
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specific serum proteins adsorbed could have differing effects on MPS uptake. 
Nanoparticles coated with human serum albumin appear more likely to be phagocytosed, 
whereas those coated with immunoglobulins show less uptake, even after being re-
introduced to whole plasma (39, 40). 
2.2.2 Effect of Micro/Nanoparticle Design Parameters on Protein Corona Formation 
Since the corona is responsible for mediating in vivo behavior of 
micro/nanoparticles, several groups have investigated how design parameters of a variety 
of micro/nanoparticle systems influences corona formation and composition. A common 
method to reduce protein adsorption to the surface of nanoparticles (and subsequent MPS 
uptake) is to surround them with PEG, which has a low affinity for most plasma proteins 
(41, 42). Several groups have found that increasing the molecular weight and surface 
density of PEG on the surface of nanoparticles results in even lower protein adsorption, 
though blocking corona formation completely remains challenging (43, 44). 
Polystyrene nanoparticles are used for a wide variety of research, therapeutic, and 
imaging applications, and can be synthesized with several different surface chemistries. 
Gessner et al. found that surfaces with acidic functional groups (which carry a negative 
charge at physiologic pH) preferentially bind proteins with an isoelectric point (pI) > 5.5, 
and vice versa. Correspondingly, the authors observed that when compared to particles 
with acidic functional groups, those with basic functional groups (e.g. NH2) bound greater 
amounts of albumin, which is negatively charged at physiologic pH (45). These results 
indicate that micro/nanoparticle-protein interactions are strongly influenced by 
electrostatic forces. 
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 The protein corona is sensitive not only to changes in particle design, but also the 
forces experienced by the nanoparticle after injection. The Payne group has recently found 
that the shear forces experienced by nanoparticles in flow can influence the composition 
of the resulting protein corona. Increased flow rate was associated with greater total protein 
content, and specifically enhanced binding of plasminogen, a precursor to the fibrinolytic 
enzyme plasminogen. Furthermore, fluorescence and circular dichroism spectroscopy 
revealed structural changes in plasminogen in response to flow, suggesting partial 
denaturation of the protein. Additionally, cellular binding to protein-nanoparticle 
complexes was found to be significantly reduced on nanoparticles exposed to flow (46). 
These results demonstrate the sensitivity of the protein corona to physiologic shear forces, 
and stress the importance of conducting protein corona research in settings that accurately 
model those conditions. 
 A simple method to modify the protein corona is pre-incubation with a desired 
protein or set of proteins. Müller et al showed that pre-treating polystyrene nanoparticles 
with plasma depleted of human serum albumin and immunoglobulins reduced the 
likelihood of aggregation when added to whole plasma (39). In a related study, it was 
demonstrated that pre-coating with immunoglobulin-depleted plasma decreases cellular 
uptake by immune cells (40). By understanding which proteins are responsible for adverse 
events such as aggregation and cellular uptake, nanoparticles can be pre-coated to avoid 
these behaviors. 
2.2.2.1 The Protein Corona of Thermoresponsive pNIPAM Microgels 
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Until recently, little was known about the corona of thermoresponsive pNIPAM 
microgels. Research has indicated that pNIPAM has low nonspecific plasma protein 
adsorption (47). However, Cedervall et al demonstrated that pNIPAM-co-N-tert-
butylacrylamide nanoparticles bound human serum antigen initially, which was replaced 
by higher affinity apolipoproteins AI, AII, AIV, and E (48). Additionally, Miceli et al. have 
recently characterized the corona of pNIPAM microgels using dynamic light scattering 
(DLS) and protein mass spectrometry (MS). Overall, they found that albumin and 
Apolipoprotein B-100 (ApoB100) were the primary corona proteins in all pNIPAM 
microgels studied. An important caveat to this research is that the pNIPAM microgels in 
this study were crosslinked with 33% dendritic polyglycerol (dPG), which enhances the 
hydrophilicity of the overall polymer network, effectively raising the LCST beyond body 
temperature. The authors state that this modification is critical to prevent hydrophobic 
collapse of the pNIPAM microgel upon intravenous injection. For comparison, control 
particles of pNIPAM crosslinked with 4% BIS were included in the analysis. Coronae from 
microgels synthesized with dPG were found to contain higher relative amounts of 
apolipoproteins such as ApoB100 and haptoglobin (HPT), although pNIPAM microgels 
without dPG (which were collapsed at 37 ˚C) bound a greater total amount of protein.  
 Notably, Miceli et al also compared the propensity of pNIPAM microgel 
formulations to aggregate in the presence of serum. All pNIPAM microgel formulations 
displayed aggregate intensity fractions of less than 30%, and the presence of dPG was 
found to completely inhibit aggregate formation at 25 ̊ C (below the LCST). dPG-pNIPAM 
microgels also showed temperature-dependent aggregation. When incubated with serum at 
37 ˚C, dPG-pNIPAM formed aggregates that were significantly reduced upon cooling to 
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25 ˚C. The authors note that the partial collapse of dPG-pNIPAM microgels at 37 ˚C led to 
enhanced adsorption of immunoglobulin (IgG) light chains, and link this event to the 
reversible formation of aggregates (49). 
 Taken together, these results point to an important characteristic of pNIPAM 
microgels: the composition of their protein corona, and their corresponding likelihood to 
aggregate in circulation, is dependent on their swelling state. Microgels that are fully 
swollen bind less protein, and specifically less aggregation-inducing IgG molecules. 
Microgels that are in a hydrophobic state, and thus partially or fully collapsed, have more 
protein-rich coronae and aggregate more readily. Notably, there is a lack of understanding 
of the influence of microgel crosslinking on protein corona formation and subsequent 
aggregation. 
2.3 Biomedical Applications of Microgels 
2.3.1 Microgel-based Strategies to Modulate Hemostasis 
Due to their micron-range size and similar softness to blood cells, microgels make 
excellent candidates for tissue engineering strategies to emulate platelets and treat 
hemostatic disorders. The Barker lab is actively involved in the development of platelet-
mimetic microgel particles to treat bleeding from thrombocytopenia, or low platelet count. 
These so-called platelet-like particles (PLPs) consist of a ULC 95% pNIPAM/5% AAc 
microgel particle functionalized with a fibrin-specific single-domain antibody fragment 
(sdFv), termed H6. H6 was screened from a library of sdFv clones using phage display, 
and was designed to bind fibrin over its circulating precursor fibrinogen. This specificity 
endows PLPs with a unique targeting ability; in theory, PLPs circulate passively in the 
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bloodstream until they encounter a nascent fibrin clot, whereupon they bind and stabilize 
the clot in a manner similar to native platelets. Notably, PLPs are capable of initiating clot 
collapse, mimicking clot contraction by native platelets, a behavior not observed in other 
synthetic platelet technologies. It is likely that the extraordinary deformability and stimuli-
responsiveness of ULC microgels enables this behavior. Most importantly, PLPs were 
found to significantly reduce bleeding time in an in vivo rat femoral vein injury model, as 
well as enhance clot formation in several in vitro systems (50). Recently, Sproul et al. have 
found that PLPs formed from hollow microgels with lightly crosslinked shells initiate fibrin 
clot collapse to a greater degree than PLPs made from microgels with traditional core-shell 
structures, supporting the hypothesis that microgel deformability is critical for clot collapse 
(5). 
 Building on this foundation, several groups have designed fibrin-targeting 
microgel-based therapies with the opposite goal: inhibiting coagulation and destabilizing 
fibrin clots. Kodlekere and Lyon recently reported on a poly(N-isopropylmethacrylamide) 
(pNIPMAM) microgel conjugated to the peptide GPRPFPAC, which mimics the fibrin 
knob ‘A.’ These microgels successfully disrupted the polymerization of stable fibrin clots, 
presumably through competitive binding to the holes ‘a’ of the fibrin molecule, a key step 
in the formation of a stable fibrin mesh (51). Furthermore, Mihalko et al. have developed 
a complex microgel system in which fibrin targeting antibodies on the microgel core direct 
the particle to existing fibrin clots. Once bound to fibrin, the microgels release both tissue 
plasminogen activator (tPA, which initiates fibrinolysis) and the small molecule cell 
contractility inhibitor Y-27632. This dual delivery system was shown to enhance blood 
flow and reduce cardiac fibrosis in vivo following myocardial infarction (52). 
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2.3.2 Microgels for Therapeutic Delivery 
Biological molecules and drugs can be loaded into microgels through covalent 
attachment to polymer chains, or using non-covalent forces such as hydrophobic 
interactions, van der Waals, or electrostatic forces. Because of their low solid content as a 
percentage of their total volume, microgels can hold 30% of their weight or more in 
therapeutic cargo. This capacity is greater than that of liposomes and polymeric micelles, 
and makes microgels ideal carriers for therapeutic delivery (53, 54). Loading microgels 
with small molecules or drugs often triggers collapse of the polymer network in a manner 
similar to the volume phase transition of thermoresponsive microgels (1). While this may 
encourage aggregation, it also presents an opportunity to design drug release systems that 
work in tandem with the stimuli-responsive nature of many microgel systems. 
2.3.2.1 Delivery of Small Molecules 
One of the most straightforward methods for loading small molecule therapeutics 
into microgels is by designing microgels with the opposite charge to the target molecule. 
This can be easily accomplished by co-polymerizing charged monomers into the microgel 
polymer network. For example, as discussed earlier, AAc can be incorporated into 
pNIPAM microgels to generate negatively-charged particles at physiologic pH. 
Alternatively, positively charged PEG-polyethyleneimine (PEG-PEI) microgels have been 
generated to carry common biologically active compounds such as retinoic acid, 
indomethacin, or valproic acid. Importantly, these loaded microgels formed stable colloidal 
suspensions and were able to by lyophilized and resuspended while still maintaining 
function (55, 56).  
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 In order to contain charged groups and control the distribution of cargo within a 
microgel, Kim et al generated PEG-b-poly(methacrylic acid) (PEG-b-PMA) which contain 
an anionic PMA core surrounded by a hydrophilic PEG shell. These microgels were 
capable of carrying up to 50 weight% of the common chemotherapy agent doxorubicin 
(DOX), which is weakly cationic. Furthermore, due to their anionic core, the PEG-b-PMA 
microgels exhibited enhanced release in acidic pH, a hallmark of tumor 
microenvironments. By adding disulfide-bonded crosslinks to the PMA core, the authors 
created microgel carriers that can be degraded on-demand by the addition of a reducing 
agent (57). 
 Microgels also offer a method to enhance the delivery of drugs that are poorly 
soluble in water, due to their tunable hydrophilicity. Wang et al. loaded paclitaxel (PTX), 
another common chemotherapy agent, into chitosan-poly(NIPAM-co-acrylamide) 
nanogels and demonstrated temperature-dependent release of the drug. Furthermore, PTX-
loaded microgels had higher anti-tumor efficacy than delivery of free PTX (58). Another 
group utilized microgels formed from lauryl-modified dextran and -cyclodextrin to carry 
benzophenone, a highly hydrophobic chemical used in sunscreen. By solubilizing 
benzophenone in the dextran and -cyclodextrin polymer solutions prior to forming 
microgels, the authors created carriers with up to 2.5 weight% benzophenone, which is 
normally completely insoluble in water (59).  
2.3.2.2 Delivery of Therapeutic Oligonucleotides 
Oligonucleotides (including small interfering RNAs (siRNAs), micro RNAs 
(miRNAs), and antisense oligodeoxynucleotides (ODNs)) have been a topic of great 
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interest in recent years, as they offer a new modality for treating diseases ranging from 
cancer to viral infections. However, due to their negative charge, it is difficult for 
oligonucleotides to penetrate cell membranes and perform their designated function (1). 
Cationic microgels are an obvious vehicle to enhance oligonucleotide delivery, and there 
have been multiple reports confirming the feasibility of this approach. 
 In one of the first examples of this strategy, Vinogradov and coworkers loaded 
cationic PEG-PEI microgels with antisense phosphorothioate ODN targeting the human 
mdr1 gene, which encodes for P-glycoprotein, involved in mediating drug-drug 
interactions. Delivering microgel-bound ODN inhibited the production of P-glycoprotein 
to a significantly greater degree than delivery of the ODN by itself (60). In recent years, 
researchers have developed a wide variety of cationic microgel formulations that allow for 
optimal oligonucleotide loading and delivery (61, 62). 
2.3.2.3 Delivery of Protein Therapeutics 
Proteins and peptides present unique delivery challenges due to their rapid 
clearance, large size compared to small molecules or oligonucleotides, limited stability, 
and potential for off-target effects. Once again, microgels are promising carriers because 
of their high loading capacity and ability to protect their cargo from degradation. Proteins 
can be passively adsorbed to microgels through hydrophobic or electrostatic interactions, 
which can stabilize hydrophobic proteins that would normally aggregate in aqueous 
solutions. However, upon injection, therapeutic proteins must compete with plasma 
proteins for the same binding sites. As a corona forms over injected microgels, therapeutic 
proteins can be lost (1). 
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Several groups have developed strategies to overcome this limitation. Hasegawa et 
al. designed “raspberry-like” assemblies of multiple cholesterol-modified pullulan-based 
microgels by crosslinking with thiol-modified tetra-armed PEG. These assemblies 
demonstrated efficient encapsulation of interleukin-12 (IL-12) and delivered a stable dose 
of IL-12 for 72 hours following subcutaneous injection (63). Nagahama and coworkers 
encapsulated lysozyme into self-assembled poly-(L-lactide)-grafted dextran microgels, and 
were able to achieve sustained release of active lysozyme for up to a week while avoiding 
initial burst release upon injection (64). 
Another method to control the release of the therapeutic protein is to take advantage 
of natural environmental cues such as pH and oxidative stress. In one example of this 
strategy, lysozyme was loaded into acid-labile microgels formed from inverse emulsion 
polymerization of N-vinylformamide with a ketal-containing crosslinker. At pH 5.8, about 
95% of the encapsulated lysozyme was released, compared to only 15% at pH 7.4 (65). To 
exploit the reducing environment inside cells, Chen et al. used reversible addition 
fragmentation chain transfer (RAFT) to polymerize disulfide crosslinked microgels 
composed of PEG-b-poly(2-(hydroxyethyl) methacrylate-co-acryloyl carbonate), which 
were used for triggered intracellular release of loaded proteins (66). 
 Cationic cholesterol-bearing pullulan (cCHP) microgels have also been 
investigated as an antigen-delivery system for adjuvant-free vaccines. Non-toxic subunit 
fragments of Clostridium botulinum type-A neurotoxin (BoHc/A) were encapsulated into 
cCHP microgels and administered intranasally. Loaded cCHP microgels were able to pass 
through mucus and bind to the nasal epithelium, where BoHc/A was taken up by mucosal 
dendritic cells (67). cCHP microgels have since been tested as vaccine carriers in clinical 
 21 
trials for therapy-refractory HER-2 positive breast cancer (68), esophageal cancer (69), and 
malignant melanoma (70). 
2.3.3 Imaging and Diagnostics 
In a manner similar to their ability to hold and deliver small molecules and proteins, 
microgels make excellent candidates for carrying imaging probes and contrast agents. 
Loading magnetic nanoparticles (e.g. iron oxide) into microgels prior to administration 
enhances both colloidal stability and magnetic resonance imaging (MRI) sensitivity over 
delivery of magnetic nanoparticles alone (71, 72). Furthermore, microgels can encapsulate 
a large quantity of magnetic nanoparticles, leading to a stronger local magnetic field (73, 
74). In a fascinating study, Okada et al. demonstrated that crosslinked PMA-based 
microgels function as MRI pH sensors by themselves, obviating the need for inorganic 
magnetic contrast agents. This surprising property is based on the collapse of PMA 
microgels at acidic pH, resulting in the restriction of water molecules interacting with 
polymer chains and a corresponding decrease in transverse relaxation time (75). 
Furthermore, microgels have been employed to mitigate toxicity from common small 
molecule MRI contrast agents such as gadolinium (76) as well as silver or gold 
nanoparticles (77, 78). 
 Microgels can also be loaded with radiotracers for use in positron emission 
tomography (PET) imaging. By crosslinking polyacrylamide-based microgels with 
polydentate chelating ligands such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA), the Almutairi group generated scaffolds for metal radionuclides such as 
64Cu. When injected into a mouse model of metastatic cancer, 64Cu-DOTA-based nanogels 
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accumulated in both the primary tumor and metastases, with minimal off-target 
accumulation in the liver or spleen (79). Microgel-based PET probes can also be designed 
to be stimuli-responsive, as Singh et al. demonstrated with reduction-sensitive partially 
thiolated poly(ethylene oxide-stat-polypropylene oxide)-based microgels that chelate 68Ga 
(80). 
 Near-infrared (NIR) imaging is the ideal fluorescence-based imaging modality for 
in vivo applications due to strong penetration of the signal through tissue and limited 
autofluorescence. However, the only approved NIR probe for clinical imaging is 
indocyanine green (ICG), which degrades quickly in aqueous media, has a low quantum 
yield, and self-quenches at sufficiently high concentration (81). To address these issues, 
and exploit the intrinsic properties of ICG, poly(-amino ester) (PBAE) nanogels were 
developed with CD44 receptor-targeting hyaluronic acid to sequester ICG in a self-
quenched (i.e. non-fluorescent) state until they reach their target site. Upon receptor-
mediated endocytosis by cancer cells, the pH sensitive PBAE is degraded, slowly releasing 
ICG and resulting in a fluorescent signal (82). Similar hyaluronic acid-containing nanogels 
have also been used to monitor hyaluronidase activity in vivo, a hallmark of cancer 
metastasis and angiogenesis (83). One particularly clever application of NIR probe-loaded 
microgels involved the use of multiple sizes of IRDye800-loaded cholesterol-modified 
pullulan (NIR-CHP) microgels to visualize cancer metastasis to regional lymph nodes. 
When injected to a primary tumor site, NIR-CHP probes with diameters >300 nm stayed 
in the primary tumor, whereas NIR-CHP probes with diameters 10 and 50 nm were taken 
up into the sentinel lymph node (SLN). Meanwhile, the smallest probes (diameters 5-10 
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nm) flowed through the SLN into adjacent nodes, allowing for complete imaging of 
lymphatic metastasis (Figure 3) (84). 
 
Figure 3: Imaging metastasis through lymph nodes with NIR-CHP microgel probes of 
varying diameter. Figure adapted from Noh et al. (84). 
In addition to imaging applications, microgels can be used to enhance the stability 
and sensitivity of enzyme-based electrochemical biosensors for diagnostic purposes. Due 
to their ease of synthesis and ability to hold a large cargo of active enzymes, microgels 
have been designed to sense choline (85, 86), phenol (87), blood esterases (88), and 
organophosphates (89). 
2.3.4 Barriers to Clinical Translation of Microgels 
Despite the significant advancement in our understanding of microgel behaviors, 
and the wide breadth of biomedical applications explored over the past several decades, 
there are vanishingly few microgel-based therapies or diagnostics in the clinical space. 
With the notable exception of cCHP microgels used for antigen delivery, no microgel 
technologies have been investigated in clinical trials. Most of the key reasons for this can 
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be grouped into two broad categories: rapid clearance, and toxicity/off-target effects. For 
a more comprehensive overview of barriers to microgel translation, the reader is directed 
to an excellent review by Soni et al. (1). 
2.3.4.1 Rapid Clearance 
The body is equipped with a number of systems to remove foreign material from 
circulation. Like most micro- or nanomaterial therapies, a primary concern is that on 
average, only 5-10% of the injected dose is actually delivered to the target site, due to 
clearance from kidneys, liver, spleen, etc. (90, 91). Splenic filtration is responsible for 
removing microgels over ~200 nm in diameter (92), whereas the kidneys may excrete 
smaller microgels directly through renal filtration (93, 94). In addition to size, the shape of 
microgels has been demonstrated to influence circulation time, with spherical microgels 
cleared more rapidly than filamentous or rod-shaped microgels (95). Furthermore, Merkel 
et al. showed that by decreasing the modulus of red blood cell-mimicking microgels by a 
factor of 8, they could extend the circulation time by 30-fold, suggesting that microgel 
stiffness is an important determinant of circulation time (96). As discussed in section 2.2.2, 
the composition and robustness of a protein corona on the surface is also correlated with 
enhanced opsonization and uptake by the MPS system. While incorporating hydrophilic 
polymers such as PEG can reduce opsonization and extend clearance time, it should be 
noted that PEG is not completely inert; antibodies to PEG are generated after a single dose, 
which results in faster clearance and reduced efficacy upon subsequent dosing (97-99). 
Finally, it is known that microgels with neutral charge circulate for longer than charged 
microgels (100, 101). However, since many microgel designs are dependent on charged 
 25 
moieties for stimuli-responsive behavior and loading of drug cargo, it is difficult to 
completely mitigate charge-dependent clearance. 
2.3.4.2 Toxicity and Off-target Effects 
Ultimately, the primary barrier to clinical translation of microgel-based technology 
is unforeseen toxicity. While there are many studies demonstrating the potential efficacy 
of microgel-based therapeutics or diagnostics, there is a critical need for research into 
associated toxicity and strategies to avoid it. Some known toxicity is related to properties 
of the microgel particles themselves. For example, in addition to accelerating clearance, 
positive charge on microgels is associated with cell shrinkage, formation of vacuoles, 
hemolysis and cell cycle disturbance (102). Loading cationic microgels with negatively 
charged cargo such as nucleic acids can shield cells from deleterious effects, but upon 
delivery of the cargo, the microgel once again displays positive charge.  
 Even without specifically targeting blood components, microgels may suffer from 
hemocompatibility issues. Naeye et al. showed that positively charged siRNA-loaded 
dextran nanogels induce platelet aggregation and bind to other blood cells, whereas 
negatively charged microgels did not (103). Negatively charged alginic aldehyde-gelatin 
microgels were also shown to be safe with respect to platelet aggregation and hemolysis, 
buttressing the argument that cationic charge leads to problems with hemocompatibility 
(104). 
 Microgels are also prone to aggregation in blood, which can result in severe 
vascular toxicity. Miceli et al. showed that BIS-crosslinked pNIPAM-based microgels with 
a diameter of approximately 250 nm in water can form aggregates in excess of 1 m 
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diameter in serum (49). Considering that microvasculature in the lung, kidneys, spleen, and 
liver can be as small as 6 m in diameter (105), these multi-microgel aggregates are close 
to a size that could occlude blood vessels, potentially resulting in vascular endothelial 
damage and inflammation, or even oxygen/nutrient deprivation in surrounding tissue. 
Deshmukh et al. exploited these properties to design stabilized PEG microgel aggregates 
to specifically target lung microvasculature on the basis of capillary diameter (106). While 
their preliminary safety data is promising, it raises a critical question: what margin of error 
separates safe lung targeting from something resembling a pulmonary embolism? As 
discussed in Section 2.2.2.1, aggregation appears to be linked to the composition and size 
of the protein corona, suggesting that strategies to control corona formation could enhance 
the safety profile of microgels in circulation.  
 Another source of toxicity is the potential for off-target effects from microgel 
formulations. A common strategy to target microgels to specific tissues or cells involves 
conjugating antibodies or receptor-specific ligands to the surface of the microgel. However, 
targeting is never fool-proof, for a variety of reasons. For one, cell surface receptors are 
rarely, if ever, completely exclusive to the target cell. As an example, folate receptor is 
overexpressed on numerous cancer cell types, but is also present on the surface of cells in 
the small intestine and kidneys (107, 108). Additionally, antibodies and other therapeutic 
proteins are sensitive to conformational change, and their targeting or therapeutic effects 
can be hindered by physical processes during microgel synthesis (e.g. shear forces from 
mixing) or chemical alterations such as pH and crosslinking (109-112). 
The PLPs described in Section 2.3.1 offer another illustration of the difficulty to 
accurately target specific proteins. The conjugated antibody fragment that bestows their 
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functionality, H6, was designed to bind fibrin over its circulating precursor, fibrinogen. 
However, H6 still possesses a moderate affinity for fibrinogen (50) – could it bind enough 
fibrinogen to nucleate micro-emboli in circulation? Furthermore, hemostasis is a dynamic 
process, balancing coagulation and clot degradation to prevent bleeding or excessive 
thrombogenesis (113). PLPs may disrupt this delicate balance by stabilizing fibrin clots 
that would normally have been dissolved, resulting in an enhanced risk for stroke or 
pulmonary embolism. Future studies are needed to elucidate the safety of these and similar 
microgel formulations.   
In summary, microgels offer a nearly limitless platform for biomedical innovation, 
yet very little microgel-based technology has actually made it to patients. Although there 
is a wealth of studies reporting proof-of-concept microgel-based therapies and diagnostics, 
research on the longer-term effects of microgels in vivo is lacking. Stated bluntly, we 
simply don’t know enough about how microgels behave in the body, and why. The central 
aim of this thesis is to explore the link between microgel crosslinking and in vivo toxicity 
to inform the rational design of microgel-based biotechnology.  
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CHAPTER 3. EFFECT OF CROSSLINK DENSITY ON 
MECHANICAL BEHAVIORS OF PNIPAM-AAC MICROGELS IN 
BIOLOGICAL FLUIDS 
3.1 Abstract 
Crosslinked microgels have been synthesized with a wide variety of polymers for a plethora 
of biological applications. Poly(N-isopropylacrylamide) (pNIPAM)-based microgels, for 
instance, are commonly crosslinked with N,N’-Methylenebisacrylamide (BIS). But while 
it has long been understood in hydrogel material science that increased crosslinking yields 
stiffer gels, there is a lack of consensus on the mechanical characterization of individual 
microgels. To address these discrepancies and build on the work performed by other 
groups, I have developed a robust atomic force microscopy (AFM)-based method for 
sampling the mechanical response of individual pNIPAM-co-acrylic acid (pNIPAM-AAc) 
microgels deposited on glass without interference from the underlying substrate. 
Furthermore, I utilize variations of this method to report, for the first time, calculation of 
the Young’s, shear, and bulk moduli of pNIPAM-AAc microgels swollen with human 
plasma, to recapitulate their in vivo environment. As expected, all moduli increase with 
increasing crosslink density. Exposure to plasma generally increases the moduli of 
microgels, though this result is inconsistent and most pronounced in highly crosslinked 
microgels. Unexpectedly, microgels did not marginate to the walls of blood vessels, 
regardless of crosslink density. Additionally, the crosslink density of microgels was found 
to not influence bulk blood viscosity. In total, though crosslink density affects the stiffness 
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of individual microgels, these differences do not affect larger scale mechanical behaviors 
of microgels in blood at common doses, such as viscosity and margination. 
3.2 Introduction 
It has long been known that the Young’s modulus of pNIPAM-based microgels can 
be enhanced by increasing the crosslink density. Research from the Lyon group 
investigated the Young’s modulus of films of ULC pNIPAM and 4% BIS-crosslinked PEI 
microgels, and yielded moduli of 10 kPa and 100 kPa, respectively (23, 24). While these 
measurements are useful for understanding relative differences in stiffness between 
microgel films, their applicability to individual microgel properties is limited, since films 
can contain 3-4 layers of microgels deposited on top of one another. Despite these findings 
and others, detailed analysis of single microgel mechanical properties, including 
characterization of shear and bulk moduli, is lacking. Furthermore, there have been no 
reports on the changes in mechanical properties that occur when microgels are immersed 
in blood plasma, which closely recapitulates their eventual environment for in vivo 
applications. 
 Notably, two studies have undertaken single-microgel AFM nanoindentation with 
vastly differing results, as discussed in Section 2.1.3. Hashmi et al. found that pNIPAM 
particles crosslinked with 3.5% BIS had a Young’s modulus of 13 kPa when swollen in 
water below the LCST, and these particles stiffened to 123 kPa when swollen with water 
heated past the LCST (21). By contrast, Tagit et al. reported that pNIPAM microgels 
crosslinked with 6.8 mol% BIS below the LCST had a Young’s modulus of 1.8 ± 0.2 MPa, 
which increased to 12.8 ± 3.6 MPa after heating past the LCST (22).  
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 This work aims to resolve the discrepancies in our understanding of single microgel 
mechanical properties, and build on this foundation by measuring bulk and shear modulus 
for these materials in a variety of solvents. I hypothesized that incubation with plasma 
results in an increase in Young’s, bulk, and shear moduli as a result of protein adsorption 
and microgel deswelling. 
In addition to analyzing the mechanical properties of single microgels, this work 
aimed to analyze the effect of microgels on the viscosity of blood, known as hemorheology. 
Blood is a complex, non-Newtonian fluid composed of a solid, cellular phase (red blood 
cells (RBCs), white blood cells, platelets) suspended in an aqueous solution of proteins, 
lipids, and salts called plasma. Blood is characteristically shear-thinning, meaning that 
apparent viscosity decreases with increasing shear. This is due to the aggregation of RBCs. 
At low shear, RBCs form reversible multicellular aggregates known as rouleaux (Figure 
4A). RBC aggregates disturb flow streamlines to a greater extent than single RBCs, 
resulting in a higher apparent viscosity. As flow rate increases, these aggregates break up 
in a shear-dependent manner, causing a decrease in the apparent viscosity. At even higher 
shear, there are practically no rouleaux, and the continued decrease in viscosity can be 
attributed to the high deformability of individual RBCs under shear (Figure 4B) (114). 
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Figure 4: Basics of hemorheology. At low shear, RBCs form multicellular aggregates 
known as rouleaux (A). As shear increases, RBC aggregates break up, resulting in a lower 
apparent viscosity. At even higher shear, individual RBC deformability accounts for a 
further decrease in viscosity (B). Figure from Baskurt et al. (114). 
 
Early in vivo studies with pNIPAM-AAc microgels indicated pulmonary toxicity 
of crosslinked pNIPAM-AAc microgels, and in vitro models of lung microvasculature 
suggested resistance to flow in these conditions, described in detail in Section 4.4. Based 
on these observations, I hypothesized that crosslinked microgels enhance the apparent 
viscosity of blood at high shear, potentially by interacting with RBCs and decreasing their 
deformability. In this chapter, I directly measured the viscosity of blood mixed with 




Figure 5: Simulation of platelet margination. As flow develops, soft RBCs cluster toward 
the center of the vessel due to lift velocity generated by the shear gradient, described by 
the Fahraeus-Lindquist effect. Platelets do not experience the same lift velocity due to their 
greater stiffness, and collide with RBCs, which push them to the margins. Figure from 
Zhao et al. (115). 
Margination is a behavior of certain blood components, including platelets and 
leukocytes, that influences the distribution of blood cells along the diameter of the blood 
vessel. In order for platelets to engage with a blood vessel injury and interact with other 
components of hemostasis, they must be present at a high concentration immediately 
adjacent to the endothelial cell layer of the vessel wall. Native platelets accomplish this 
through a process called margination. High shear flow (such as that experienced in 
microcirculation) causes deformable red blood cells (RBCs) to generate a lift velocity away 
from the wall of the vessel, resulting in an RBC-free layer known as the Fahraeus-Lindquist 
effect. Platelets are about an order of magnitude more rigid than RBCs, and thus do not 
exhibit the same behavior. Additionally, the comparatively rigid platelets colliding with 
deformable RBCs in flow introduces a shear-induced diffusion of platelets from the RBC-
rich region. The net effect is that platelets end up trapped in the RBC-free layer near the 
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vessel wall, as seen in Figure 5 (115-117). I hypothesized that microgel margination could 
be enhanced by increasing the crosslink density of microgels, resulting in a higher effective 
dose of microgels at the vessel wall. Using a particle tracking algorithm in a microfluidic 
channel, I analyzed the degree to which microgels of varying crosslink density marginate 
in whole blood. 
3.3 Materials and Methods 
3.3.1 pNIPAM-AAc Microgel Synthesis 
The synthesis protocol for pNIPAM-based microgels is reviewed in detail in other 
publications (14, 16, 118). Briefly, NIPAM (Sigma Aldrich) was recrystallized in hexane 
prior to use. Acrylic acid (AAc) (VWR), ammonium persulfate (APS) (ThermoFisher), and 
BIS (Sigma Aldrich) were all used as received. 100 mL of deionized water was added to a 
clean 250 mL round bottom flask using a filtered syringe. The water was stirred at 650 rpm 
throughout the synthesis procedure. 1.8 g of NIPAM was dissolved in 20 mL of deionized 
water and added to the reaction flask through a filtered syringe. BIS was also added at this 
step if synthesizing exogenously crosslinked microgels. N2 gas was bubbled through the 
solution as it heated to 70 ̊ C.  AAc was diluted in 1 mL of deionized water prior to addition 
to the reaction through filtered syringe for a final concentration of 5 mol%. After 10 
minutes of mixing, the N2 needle was lifted over the solution to create a blanket of N2 over 
the reaction. To initiate, 36 mg of APS was dissolved in 4 mL of deionized water and added 
to the reaction through a filtered syringe. Initiation was confirmed by visual observation of 
increasing opacity of the solution, changing from clear to light blue to milky white within 
2-3 minutes. The reaction was run overnight, maintaining temperature at 70 ˚C. After 
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allowing the reaction to cool, large aggregates were filtered out using glass wool, and the 
microgels were purified by dialysis against deionized water with a 30 kDa molecular 
weight cutoff membrane. Microgels were lyophilized for long-term storage. 
3.3.2 Immobilizing Microgels on Coverslips 
12 mm diameter glass coverslips were cleaned according to the following protocol: 
20 minute bath sonication in deionized water with Alconox detergent (Sigma Aldrich), 15 
minute bath sonication in deionized water, 15 minute bath sonication in acetone, 15 minute 
bath sonication in absolute ethanol, 15 minute bath sonication in absolute isopropyl alcohol 
(IPA). Cleaned coverslips were stored in absolute IPA prior to use. To prepare for microgel 
deposition, coverslips were placed in wells of a 24-well plate and dried with compressed 
air. Coverslips were then silanized by adding 0.5 mL of 1% (v/v) (3-
Aminopropyl)trimethoxysilane (Sigma Aldrich) in absolute ethanol to each well and 
incubating for 1 hour at room temperature. Wells were washed once with absolute ethanol 
and three times with deionized water. Microgels were suspended in deionized water at a 
concentration range of 0.01-0.001 mg/mL and 0.5 mL of each suspension was added to the 
cleaned, silanized coverslips in the well plate. Microgels were left to deposit passively 
overnight at room temperature, before being rinsed three times with deionized water to 
remove unbound microgels. Prepared coverslips were left hydrated in deionized water for 
up to 1 month after functionalization to avoid artifacts from drying/rehydrating cycles. 
3.3.3 AFM Tip Calibration 
Silicon nitride AFM cantilevers were purchased with a 1 m diameter polystyrene 
bead attached to the end of the tip (Novascan). The nominal spring constant of the tips used 
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for these studies was 0.02 N/m. The tip was calibrated at the beginning of each experiment 
according to the following procedure: After submerging the tip in the solvent used for that 
experiment, the tip was allowed to equilibrate to temperature until the deflection stayed 
constant for several minutes. A single force measurement against glass was then taken, 
from which the deflection inverse optical level sensitivity (DefInvOLS) and virtual 
deflection line were measured. The tip was then raised away from the surface of the glass, 
and thermal fluctuation data was gathered to complete the spring constant calibration in 
Asylum software (Oxford Instruments). 
3.3.4 Single Microgel Force Mapping 
Microgel-coated coverslips were submerged in the desired solvent, and both the 
coverslip and the AFM tip were allowed to equilibrate to temperature. Unless otherwise 
specified, measurements were taken at 25 ˚C. Next, a 10 m by 10 m force map was 
created in tapping mode with a 450 pN trigger force, 750 nm force distance, and 1.8 Hz 
scan rate. Individual microgel particles were located from this map, and an appropriate x-
y offset was selected to move the tip to a single microgel, which was imaged with a 2 m 
by 2 m force map with the same parameters. 
3.3.5 Generation of Force vs. Indentation Curves 
After obtaining a force map of a single microgel, the “nudger” feature was used to 
move the AFM tip to the center of the microgel particle. A macro was built in Asylum to 
perform a number of different indentations. First, trigger force was held constant at 350 pN 
while approach velocity was increased from 2 m/s to 12 m/s, in 2 m/s increments. Next, 
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approach velocity was held constant at 2 m/s, with an added three second “dwell” after 
indentation. The trigger force was then decreased from 350 pN to 110 pN in 40 pN 
increments. Four measurements were taken for each set of parameters. 
3.3.6 Calculation of Young’s, Shear, and Bulk moduli 
Calculation of mechanical properties was based primarily on the Hertz model of 
contact between two spheres (Equation 1), where F is force, Rc is the radius of curvature 
of the tip,  is the Poisson ratio of the microgel, E is the Young’s modulus, and  is the 
indentation depth of the tip. Importantly, the Hertz model is only accurate for synthetic 
gels for small deformations (strain < 0.05), so indentation depth was carefully monitored 
throughout all measurements (119). 
            (1) 
To solve for shear modulus (G), it was necessary to use the elastic conversion 
formula in Equation 2, where K is bulk modulus: 
            (2) 
The shear measurements were performed at sufficiently high velocity to avoid 
deswelling of the microgel, determined empirically by taking shear measurements at 
increasing velocity, shown in Figure 6. 














Figure 6: Representative graph of measured shear modulus vs AFM tip speed for one 8% 
BIS microgel swollen in water. For each speed, four measurements were taken. After an 
initial decrease in measured modulus from 2 m/s to 4 m/s, the modulus levels out up to 
12 m/s. The tip speed selected for measuring shear was the highest speed for which a 
measured force vs. indentation slope had an acceptable goodness of fit (R2 > 0.9). 
Because of this, I assume that the material is incompressible, i.e. K → ∞. Taking 
the limit of Equation 2 as K→∞ results in the expression E = 3G, as shown in Equation 3: 
           (3) 
If I assume that the material is incompressible, I can also set the Poisson ratio  = 
0.5. Taken together, these substitutions result in the Equation 4 used to calculate G. By 
raising the known indentation depth  to the 2/3 power, and calculating the slope of the 
resulting force versus modified indentation curve at low indentation depth, G can be solved 
for each measurement. A representative set of data used for this analysis can be seen in 
Figure 7. 
















Figure 7: Analysis of shear modulus for a representative microgel. A, the raw force vs. 
indentation curve exported from the AFM software. B, the curve was smoothed with a 
radius of 80 data points to reduce thermal noise from the AFM tip. C, the curve was zeroed 
at the contact point, determined by the AFM software and corrected by visual interpretation 
of each curve. D, magnified view of the contact region. E, contact region force vs. 
indentation linearized by raising the indentation to the 3/2 power, as per the Hertz model. 
Note the “kink” in the force curve about halfway through indentation, indicating that the 
Hertz model no longer applies. For this reason, all measurements were taken from the slope 
measured in the early, linear region of the curves.  
A similar method can be used to calculate bulk modulus, though the interpretation 
of the force versus indentation curve is more complex. For these measurements, the tip was 
“dwelled” at increasing trigger points for 3 seconds, and the resultant force at the end of 
the dwell curve was read as the force at that specific indentation. For most dwell curves, 
the relaxation from the initial indentation was on the order of milliseconds (Figure 8B).  
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Figure 8: Example of a dwell force curve. A, Force vs indentation. B, Force vs. time. The 
initial extension is shown in red, and the dwell is shown in purple.  
The force versus indentation curve was then manually constructed from these 
points. Additionally, since the microgel was deswelling, and thus compressing,  could no 
longer be set to 0.5. Instead, the elastic conversion formula for  in terms of K and E was 
used (Equation 5), since E was already known for each particle from the shear 
measurements described above. 
           (5) 
This expression was substituted back into Equation 1 to yield the following 
Equation 6, used to solve for K. A representative set of data used for this analysis can be 
seen in Figure 9. 
         (6) 
















Figure 9: Analysis of bulk modulus for a representative set of microgels (each microgel is 
a different color curve). A, measured force at the end of 3 seconds of dwelling on each 
microgel vs. the set trigger point. B, the same force data, plotted against the measured 
indentation at the trigger points in A. C, Force vs Hertz-linearized indentation, showing 
slope fit for each microgel.  
3.3.7 Dynamic Light Scattering Measurements of Microgels 
Microgels were suspended in various solvents at a dilute concentration (0.01 
mg/mL). Laser scattering was measured using a 3D dynamic light scattering instrument 
(LS Instruments) and analyzed with a custom-built MATLAB script from the Fernandez-
Nieves lab to extract hydrodynamic radius for each microgel species. More details on 
analysis of light scattering can be found in a previous publication by Sierra-Martin et al. 
(120). 
3.3.8 Calculation of Volume Fraction 
Volume fraction represents the amount of space taken up by a particular species compared 
to the total volume of the sample. Normally, it is calculated using Equation 7, where  is 
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volume fraction, Nparticles is the number of particles in the sample, Vswollen is the volume of 
one particle at its maximum swollen state, and Vtotal is the total volume of the sample. 
           (7) 
However, since the number of particles (or in this case, microgels) is particularly 
difficult to quantify due to the near-transparent nature of swollen pNIPAM microgels, a 
different calculation is required. The mass concentration of microgels can be determined 
gravimetrically, i.e. by weighing out larger quantities of lyophilized microgels (> 5 mg) 
and adding a known volume of solvent. An ideal expression would relate the resulting mass 
per volume concentration (mg/mL) to volume fraction. Toward this goal, we can utilize 
what we know about the mass of microgels added, described in Equation 8, where msolid is 
the mass of microgels added, Vcollapsed is the volume of one microgel completely collapsed 
(i.e., not swollen with solvent), and  is the density of NIPAM (1.1 g/cm3). 
          (8) 
Solving for the unknown Nparticles and substituting back into Equation 7 yields the 
following Equation 9 that relates mass per volume to volume fraction. The central term 
(Vswollen/Vcollapsed) is commonly referred to as the “swelling ratio” and can be determined 
by DLS measurements of microgel size at varying swollen states. 
          (9) 




𝑚𝑠𝑜𝑙𝑖𝑑 = (𝑁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠)(𝑉𝑐𝑜𝑙𝑙𝑎𝑝𝑠𝑒𝑑)(𝜌𝑁𝐼𝑃𝐴𝑀) 











There are a few caveats to the above analysis which should be noted. For one, the 
exact mass of microgels added to the solvent can be difficult to measure precisely – even 
when working with masses > 5 mg, the accuracy of the balance used to measure may vary 
by ± 0.1 mg, as per the Mettler Toledo website (www.mt.com). Furthermore, the density 
term only accounts for the density of NIPAM. Since all microgels in this analysis contain 
5 mol% AAc (density 1.05 g/cm3), and some contain BIS (density 1.24 g/cm3), the actual 
density of each sample may vary slightly. But since NIPAM makes up the vast majority of 
the polymer network, and the densities of AAc and BIS are similar to that of NIPAM, these 
differences are likely negligible. By far, the most important source of uncertainty in 
calculating volume fraction with Equation 9 is the swelling ratio. While DLS can provide 
accurate size measurements of microgels in various solvents, a true swelling ratio would 
relate the size of microgels swollen in blood, complete with plasma as well as cellular 
components, to their dry state. The measurements reported cannot replicate these exact 
conditions, and thus the volume fractions should be interpreted as a close estimate, and 
viewed in relation to one other instead of as an absolute determination. 
3.3.9 Hemorheological Analysis of pNIPAM-AAc Microgels in Whole Blood 
Blood was drawn into sodium citrate to prevent coagulation, and mixed with 
microgels at a concentration of 1 mg/mL. 4 mL of the blood mixture was loaded into an 
Anton-Paar rheometer. Rotational shear rate ranging from 0.01 to 10,000 s-1 was applied 
to the mixture, and the resultant viscosity was analyzed for each shear rate.  
3.3.10 Evaluation of pNIPAM-AAc Microgel Margination in Whole Blood 
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To assess the degree to which pNIPAM-AAc microgels marginate to the edges of 
blood vessels, Cy3b-labeled microgels of varying crosslink density were mixed with 
citrated whole blood at an approximate concentration of 200,000 microgels/L, to mimic 
the concentration of native platelets. The mixed blood was then perfused through a 150 m 
wide x 150 m tall straight microfluidic channel at a physiologic shear of 1 dyne/cm2. A 
custom-written MATLAB code (in collaboration with Meredith Fay from the Lam lab) was 
used to count the individual microgels and track their location within the channel from 
confocal microscopy videos. In certain experiments, native platelets were labeled with an 
antibody against CD41 (Novus Biologics) to compare against platelet margination. 
3.4 Results 
3.4.1 Young’s, Shear, and Bulk moduli of pNIPAM-AAc Microgels 
The summary of AFM nanoindentation modulus measurements for ULC, 2% BIS, 
and 8% BIS microgels is shown in Table 1. To assess the changes in mechanical properties 
upon immersion in physiologic liquids, measurements were collected after swelling 
microgels with either deionized water (DI H2O), phosphate-buffered saline (PBS), or 








Table 1: Summary of AFM nanoindentation experiments on pNIPAM-AAc microgels of 
varying crosslink density. Young’s (E), shear (G), and bulk (K) moduli were calculated as 
described in section 3.3.6. N ≥ 5 microgels for each condition, with the median of 4 
measurements being calculated for each individual microgel. Data is reported as mean ± 
standard deviation.  
E (kPa)  ULC 2% BIS 8% BIS 
 DI H2O 2.71 ± 1.74 10.87 ± 4.31 9.91 ± 4.96 
 PBS 2.79 ± 1.28 7.34 ± 1.56 7.65 ± 2.59 
 Plasma 5.63 ± 1.40 8.26 ± 1.99 22.64 ± 10.74 
G (kPa)  ULC 2% BIS 8% BIS 
 DI H2O 0.90 ± 0.58 3.62 ± 1.44 3.30 ± 1.65 
 PBS 0.93 ± 0.43 2.45 ± 0.52 2.55 ± 0.86 
 Plasma 1.88 ± 0.47 2.75 ± 0.66 7.55 ± 3.58 
K (kPa)  ULC 2% BIS 8% BIS 
 DI H2O 0.37 ± 0.25 1.56 ± 0.72 1.31 ± 0.70 
 PBS 0.36 ± 0.16 1.03 ± 0.29 0.99 ± 0.39 
 Plasma 0.77 ± 0.18 1.11 ± 0.31 3.52 ± 1.95 
 
The modulus measurements displayed high variability, as reflected in the standard 
deviations reported. As expected, ULC pNIPAM-AAc microgels were the softest measured 
in all moduli, regardless of solvent. Microgels crosslinked with 2% BIS exhibited an 
approximately 4-fold increase in stiffness when swollen with deionized water. Increasing 
the crosslink density further to 8% had a negligible effect on modulus measured in 
deionized water or PBS. Comparing similar microgels swollen with either deionized water 
or PBS, it seems that ULC microgels are agnostic to the increased salt concentration of 
PBS. BIS-crosslinked microgels appear to soften slightly when swollen with PBS, but this 
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is not significant (ANOVA, Tukey’s posttest). Swelling with human plasma greatly 
enhances the measured moduli of ULC and 8% BIS-crosslinked microgels, but has minimal 
effect on 2% BIS-crosslinked microgels. In total, the bulk moduli of all microgels was 
lower than their respective shear moduli, indicating that compressing pNIPAM-AAc 
microgels requires less force than shearing them. 
3.4.2 Height Profiles of pNIPAM-AAc Microgels on Glass 
While gathering force versus indentation measurements for pNIPAM-AAc 
microgels, AFM force maps of individual microgels were also obtained. These maps are 
contain height information on microgels deposited on glass, though not in the usual contact 
mode that is employed when generated height maps with AFM. Instead, each “pixel” of 
the image is a single indentation of the tip, and records the height at which the set trigger 
force was reached. By normalizing the height information of force maps of various 
microgels, we can gather a relative comparison of microgel shape after swelling with 
different solvents, as seen in Figure 10. 
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Figure 10: Height profiles of individual pNIPAM-AAc microgels of increasing crosslink 
density immobilized on glass and swollen with various solvents. Height information was 
obtained through force maps of individual microgels, where each pixel is one indentation. 
ULC microgels immobilized on glass spread to a diameter of approximately 1.5 m 
when rehydrated in deionized water, and reach a maximum height of about 300 nm. Their 
diameter is slightly less in PBS or plasma, though their height remains the same. Microgels 
crosslinked with 2% BIS maintain a diameter of slightly over 1 m in all solvents, and 
swell to a height between 600 and 700 nm. Microgels crosslinked with 8% BIS show a 
more similar morphology to microgels crosslinked with 2% BIS than to ULC microgels, 
though they maintain a greater height, with most microgels reaching at least 700 nm above 
the glass surface. 8% microgels also have a much more clearly defined edge between the 
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microgel and surrounding glass, whereas 2% BIS microgels, and particularly ULC 
microgels, show a more gradual transition from microgel to glass. This difference is 
especially pronounced in the 8% BIS microgels swollen with plasma. These morphological 
distinctions reflect the differences in internal structure of pNIPAM-AAc microgels that 
arise from increasing crosslink density, and the rigid boundary observed with 8% BIS 
microgels swollen with plasma suggests changes in the way that these microgels form a 
protein corona when exposed to blood plasma. 
3.4.3 Swelling Behaviour and Volume Fraction of pNIPAM-AAc Microgels 
In order to predict the behavior of microgels in vivo, it is necessary to understand how they 
swell in response to various environmental conditions. Beyond providing information 
about size, pNIPAM microgel swelling behavior is indicative of the hydrophobicity of the 
polymer chains that comprise the microgel (2). The most straightforward way to measure 
microgel swelling behavior is through DLS analysis of microgel size with varying solvents 
and temperatures. Ideally, microgel size in whole blood should be interrogated; however, 
the opacity of blood due to the presence of other suspended objects such as cells precludes 
this analysis. Instead, two conditions were designed to mimic the “collapsed” and 
“swollen” states of the microgels. For the “collapsed” condition, pNIPAM-AAc microgels 
were suspended in deionized water with 150 mM NaCl, pH 3, at 60 ˚C. The NaCl 
encourages collapse of the microgels through osmotic pressure, and the pH of 3 is below 
the pKa of acrylic acid (pKa 4.2), ensuring that the vast majority of acrylic acid groups are 
protonated and therefore not ionized. Finally, raising the temperature of the solution to 60 
˚C places the microgels well above their volume phase transition temperature (VPTT). For 
the “swollen” state, microgels were suspended in phosphate buffered saline at 37 ˚C. It is 
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important to note that these conditions are not indicative of the maximum swollen state of 
pNIPAM-AAc microgels. For maximum swollen size, microgels should be suspended in 
deionized water at pH 9, where their acrylic acid groups are ionized, thus stabilizing the 
swollen conformation through intraparticle charge repulsion. Additionally, to observe 
microgels in their fully swollen state, their temperature should be lowered to well below 
their VPTT, such as 15 ˚C. But for these studies, we are interested in studying microgels 
as swollen as they would be in physiologic settings. Table 2 shows the size measurements 
of pNIPAM-AAc microgels of varying crosslink density in collapsed and physiologically 
swollen states, as well as their swelling ratios. 
Table 2: Hydrodynamic radius (Rh) of pNIPAM-AAc microgels in collapsed and 
physiologically swollen states, as measured by DLS. Data is reported as mean ± standard 
error. The swelling ratio was calculated by dividing the physiologically swollen volume 
(Vs) by the collapsed volume (Vc), assuming a spherical shape. 
 ULC 2% BIS 8% BIS 
Physiologically Swollen Rh (nm) 810 ± 48 442 ± 18 379 ± 11 
Collapsed Rh (nm) 690 ± 18 376 ± 7 333 ± 11 
Swelling ratio (Vs/Vc) 1.62 1.62 1.47 
 
ULC microgels display a larger hydrodynamic radius (Rh) than BIS-crosslinked 
microgels in both collapsed and physiologically swollen states, and Rh decreases 
monotonically with the degree of crosslinking. All microgels exhibited significant collapse 
upon suspension in acidic solution above the VPTT, as reflected in the swelling ratio 
(Vs/Vc). However, microgels crosslinked with 8% BIS had a slightly lower swelling ratio, 
indicating a lesser degree of collapse than microgels with lower crosslink density. This 
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might suggest that the high crosslink density of 8% BIS microgels confers a resistance to 
collapse in physiologic conditions.  
 Preliminary biodistribution and clearance time experiments, discussed in detail in 
Section 4.4, were modeled after hemostasis studies with fibrin-targeting microgels 
developed as synthetic platelet-like particles. The peak blood concentration ranged from 1-
1.5 mg/mL, and this was used as a reference concentration for most of the in vitro and in 
vivo experiments throughout this work. It is useful to calculate the volume fraction of 
microgels in blood resulting from this concentration, both to understand the relative space 
the microgels occupy and to investigate whether changes in swelling behavior between 
microgels of different crosslink density result in different volume fractions while holding 
mass concentration the same. Table 3 shows the approximate volume fractions calculated 
for each microgel type based on the swelling behavior in Table 2. 
Table 3: Approximate volume fraction of microgels of varying crosslink density at 1 
mg/mL. 
At 1 mg/mL ULC 2% BIS 8% BIS 
 0.0015 0.0015 0.0013 
While 8% BIS microgels have a slightly lower volume fraction that ULC or 2% 
BIS microgels, owing to their lower swelling ratio, the difference is nearly negligible 
compared to the miniscule volume fraction occupied by all microgels. Regardless of 
crosslink density, it is abundantly clear that at this mass concentration, the pNIPAM-AAc 
microgels occupy a vanishingly small percent of the total volume of blood upon injection 
and mixing. Even at 10 times the injected dose, the microgels would take up less than 2% 
of the volume of blood. 
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 As mentioned previously, an ideal calculation of volume fraction would be based 
on DLS measurements of microgel size in whole blood, or at least blood plasma, in order 
to include the effects of plasma protein binding. Unfortunately, DLS measurements of 
microgels suspended in filtered plasma were inconclusive. The only condition where there 
DLS analysis yielded reliable results were for the 8% BIS microgels at 14 ˚C, where an Rh 
of about 150 nm was detected. For all other microgel conditions, and even for plasma alone, 
the light scattering was dominated by a species with an Rh of approximately 60 nm. Since 
this was detected in plasma by itself, it is likely that this is simply particulate matter in 
plasma that was too small to be filtered out. 
3.4.4 Hemorheology of pNIPAM-AAc Microgels in Whole Blood 
To assess whether pNIPAM-AAc microgels affected the bulk viscosity of human 
blood at relevant in vivo concentrations, microgels of varying crosslink density were mixed 
with whole blood and measured over a range of shear rate with a rheometer. Figure 11 
shows the viscosity results ranging from a shear rate of 0.01 s-1 to 10,000 s-1. 
 
Figure 11: Rheological analysis of apparent blood viscosity vs applied shear rate for 
various microgel conditions. A, full range of shear rates from 0.01 s-1 to 10,000 s-1. B, 
zoomed in results for 0.1 s-1 to 1 s-1. Data presented as mean ± standard error, N = 3.  
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Overall, pNIPAM-AAc microgels at 1 mg/mL had minimal, if any, effect on the apparent 
bulk viscosity of blood over a range of physiologically relevant shear rates. Figure 11B 
shows that from 0.1 s-1 to 1 s-1, ULC microgels potentially increase the apparent blood 
viscosity, though this effect was highly variable between experiments and not significant. 
In all conditions, blood showed characteristic shear-thinning behavior until approximately 
2000 s-1, at which point the apparent viscosity began to rise again. This occurred even with 
whole blood without any microgels. However, since this shear rate is outside the normal 
range of physiologic shear, it is likely that the apparent rise in viscosity is due to destruction 
of red blood cells, known as hemolysis (114). 
3.4.5 Margination of pNIPAM-AAc microgels in whole blood 
Preliminary studies of ULC and 2% BIS-crosslinked pNIPAM-AAc microgels suggested 
that 2% BIS microgels may marginate more effectively than ULC microgels, ostensibly 
due to their greater shear modulus. To test this effect, margination studies in whole blood 
were carried out with ULC, 2%, and 8% BIS-crosslinked microgels, as well as with labeled 
human platelets. Blood was mixed with the microgels, and perfused through a straight 
microfluidic channel (150 m tall by 150 m wide) at physiologic wall shear of 1 
dyne/cm2. The results, plotted as a histogram of microgel or platelet locations along the 
width of the channel, are shown in Figure 12. 
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Figure 12: Representative results of margination studies with pNIPAM-AAc microgels 
and human platelets. A, schematic of microfluidic margination experimental setup (adapted 
from (121)). B, Labeled example of fluorescent particles flowing through the microfluidic 
channel. C-F, histogram results of microgel or particle locations across width of 
microfluidic channel. 
Figure 12F demonstrates that human platelets marginate to the walls of the 
microfluidic channel as expected. However, all microgel conditions studied were highly 
variable, and very few showed any consistent margination behavior. The potential 
margination toward the wall with ULC microgels in Figure 12C was primarily due to 
adhesion to the wall of the microfluidic channel, and was not true margination.  
3.5 Discussion 
3.5.1 Interpretation of Single-microgel Mechanical Properties and Swelling Behavior 
Prior to this work, AFM studies on the mechanical properties of individual 
microgels were limited, in part due to concern over the influence of the underlying substrate 
on measured mechanical properties (23). Furthermore, groups that have measured single 
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pNIPAM microgels with AFM through the VPTT have arrived at drastically different 
values, as discussed in Section 3.2.  The work in this thesis was not focused specifically on 
probing changes in microgel mechanics throughout the VPTT, but yielded results with 
swollen microgels in water that are much closer to those of Hashmi et al. Furthermore, the 
methods employed here to ensure linearity of force vs indentation after application of the 
Hertz model, and the careful selection of force curves to limit analysis to only the first 20-
40 nm of indentation depth, minimizes the risk of substrate influence, i.e. sampling the 
glass underneath the microgels.  
 The results presented here show that pNIPAM-AAc microgels, regardless of 
crosslink density, do not measurably stiffen when swollen with deionized water vs. PBS 
(Table 1). In fact, BIS-crosslinked microgels appear to soften slightly with the addition of 
the ions from PBS, though this result is not significant. This is somewhat surprising, since 
the addition of salts from PBS is expected to promote microgel collapse, both by shielding 
the intraparticle electrostatic repulsions from negatively charged AAc groups, and inducing 
osmotic pressure (20). A possible explanation is that even with the added ions of PBS, the 
VPTT of the microgels is still above the range of temperatures studied here (25-37 ˚C), 
meaning that the microgels have not yet begun to collapse. 
When exposed to human plasma, ULC and 8% BIS microgels exhibit an 
approximate 2-fold increase in modulus when compared to those swollen in water or PBS. 
Two potential mechanisms could be at work: One is that plasma proteins and ions could 
cause microgel deswelling, resulting in an increase in modulus. The other is that plasma 
proteins adsorb to the surface of the microgels, resulting in a stiffer layer of proteins that 
is probed by the AFM tip. To tease out the relative contributions of these two options, it is 
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useful to re-examine the studies by Tagit et al. and Hashmi et al. discussed above. While 
there exists a stark contrast in the absolute modulus measurements between the two, the 
relative increase in modulus before and after the VPTT is similar – microgels tend to 
increase in Young’s modulus by approximately an order of magnitude after their VPTT. 
Since microgels exposed to plasma did not stiffen to this degree, it is unlikely that the 
plasma caused them to fully collapse. Furthermore, Figure 10 demonstrates that the height 
of microgels swollen with water, PBS, or plasma is relatively similar. If collapse were 
occurring, it should be detectable by AFM height profiles, as observed in the study by 
Hashmi et al. (21). From these observations, it seems more probable that the increase in 
stiffness is due to the adsorption of a protein corona onto the surface of microgels. 
However, there is some evidence that microgels may collapse slightly upon 
exposure to plasma, even if it is not enough to influence their mechanical properties as 
dramatically as would be expected for a full volume phase transition. While AFM 
measurements are appropriate for measuring the relative changes in modulus for different 
crosslinking and solvent conditions, the process of immobilizing microgels on glass may 
artificially stabilize the swollen conformation, resulting in an inaccurate VPTT. For a more 
accurate representation of swelling behavior, DLS is more appropriate. Table 2 showed 
that while all microgels are larger at physiologic saline and temperature than at conditions 
designed for maximum collapse, 8% BIS microgels had a smaller swelling ratio. In other 
words, it was harder to collapse 8% BIS microgels to the same degree as ULC or 2% BIS 
microgels. This is in agreement with early studies on pNIPAM microgel swelling by Gao 
and Frisken (16). Furthermore, DLS measurements of microgels suspended in plasma were 
largely inconclusive – ULC and 2% BIS microgels showed the same background scattering 
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as plasma alone. But for 8% BIS microgels in plasma at 14 ˚C, a consistent species with 
Rh of 150 nm was detected. It may be that when incubated with plasma, the higher crosslink 
density of 8% BIS microgels prevents their complete collapse in plasma, whereas 
microgels of lower crosslink density collapse completely. If this is true, the ramifications 
for in vivo mechanical properties are tremendous – all microgels would likely have 
apparent moduli close to an order of magnitude higher than those reported here. Before 
claiming this, however, more research on the swelling behavior of microgels in plasma is 
warranted. 
3.5.2 Microgel Hemorheology and Margination in Whole Blood 
My hypothesis that microgels may influence the bulk viscosity of blood was 
motivated in part by findings that other nanoparticle systems increase blood viscosity, 
particularly by enhancing hemolysis and stiffening red blood cells upon exposure to 
nanoparticles (122). Additionally, my hypothesis was based on preliminary findings of 
apparent resistance to flow of whole blood mixed with crosslinked microgels in a 
microfluidic model of lung microvasculature, discussed in detail in Section 4.4. 
Correspondingly, I hypothesized that crosslinked microgels would enhance apparent blood 
viscosity at high shear rates such as those experienced in lung microvasculature. Instead, 
Figure 11 shows that the bulk viscosity of blood is largely unaffected by microgels of any 
crosslink density, even at especially high shear. In retrospect, this result may be 
unsurprising. For one, microgels at their physiologic concentration of 1 mg/mL occupy a 
volume fraction between 0.0013 and 0.0015, as per Table 3. This volume fraction is 
miniscule compared to the volume fraction of the cellular components of blood, commonly 
referred to as hematocrit, which ranges from 0.39-0.54 in healthy adults (123). 
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Furthermore, if microgels were indirectly influencing blood viscosity by affecting 
erythrocyte morphology, stiffness, or aggregation, I would expect to see evidence of this 
in microscopy experiments mixing microgels with whole blood. Instead, studies of 
microgels mixed with labeled erythrocytes, platelets, and neutrophils showed that 
microgels were largely ignored by other blood components.  
 The finding that increasing microgel crosslinking does not lead to increased 
margination was unexpected. As discussed in section 3.2, the Fahraeus-Lindquist effect 
predicts that RBCs cluster toward the center of a blood vessel due to the lift velocity 
generated by the gradient of shear stress. Platelets, which are about an order of magnitude 
stiffer than red blood cells, do not experience this force as strongly, and instead end up 
trapped in the “cell free layer” near the vessel wall (115-117). It follows that microgels, 
which have tunable stiffness in the same range as red blood cells and platelets as seen in 
Table 1, should show tunable margination as well. However, Figure 12 demonstrates that 
regardless of crosslink density, microgels do not reliable marginate to the walls of the 
microfluidic channel. There are a few potential explanations for this finding. One is that 
the difference in shear modulus between ULC and BIS-crosslinked microgels is simply not 
great enough to lead to obvious changes in margination. At a recent meeting of the World 
Congress of Biomechanics, Chachanidze et al. showed that red blood cells can be 
encouraged to marginate dramatically by fixing them with glutaraldehyde. However, 
normal RBCs display a Young’s modulus of approximately 1 kPa, as opposed to 2-3 MPa 
for glutaraldehyde-fixed RBCs – a difference in modulus of over three orders of magnitude 
(124). As per Table 1, there is only about a 4-fold difference in modulus between ULC 
and 8% BIS crosslinked microgels in plasma. Another complicating factor is the size of 
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microgels in plasma. At approximately 1 m in diameter, microgels are smaller than all 
other blood cells, including platelets. Since platelet margination in whole blood depends 
on platelets colliding with RBCs and being forced to the cell-free layer, it is possible that 
microgels are too small to be affected by these collisions, and may slip between RBCs 
without being pushed to the margins. Further studies on controlling microgel margination 
in blood vessels should incorporate larger microgel particles, as well as a wider range of 
moduli. 
3.6 Conclusion 
Understanding the mechanical properties of microgel particles is crucial to predicting 
their in vivo behavior in almost any biological application. In this chapter, I outline a robust 
AFM-based method for investigating the Young’s, shear, and bulk moduli of pNIPAM-
based microgels. To the best of my knowledge, this work also represents the first report of 
how microgel stiffness changes upon incubation with human blood plasma, which is most 
representative of their eventual in vivo environment. In general, pNIPAM-AAc microgels 
exhibit an increase in modulus when exposed to plasma, though this response is most 
dramatic with highly-crosslinked microgels. Surprisingly, altering microgel stiffness does 
not measurably affect margination of microgels in whole blood; on the contrary, it appears 
that pNIPAM-AAc microgels in this size and stiffness range do not reliably marginate to 
the walls of blood vessels. Furthermore, microgels at common doses for therapeutic 
delivery and targeting do not affect bulk blood viscosity. This information will help to 
inform future work on injectable microgel-based therapies. 
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CHAPTER 4. EVALUATION OF PNIPAM-AAC MICROGEL 
AGGREGATION AND PULMONARY TOXICITY 
4.1 Abstract 
A major obstacle to the clinical translation of microgel-based technology is short 
half-life in blood and uptake by immune cells. While rapid clearance may be ideal for short-
term delivery in acute conditions, it presents a challenge for chronic disease treatment or 
long-term imaging applications. In this work, I explore the effect of increasing crosslink 
density on blood clearance time and biodistribution. Overall, I find that the majority 
microgels are cleared from blood within 12 hours, regardless of crosslink density. 
However, microgels of higher crosslink density tend to accumulate in the lungs for at least 
24 hours, and in the kidneys for at least 72 hours. Ultralow crosslinked (ULC) microgels 
appear to accumulate to a lesser degree. While conducting these studies, I also observed a 
crosslink-dependent pulmonary toxicity in some mouse models, which motivated an 
investigation into the mechanism behind this toxicity. I find that crosslinked microgels 
form a larger and more numerous aggregates in plasma that can occlude lung 
microvasculature. While this does not necessarily lead to whole-lung inflammation in all 
animals that receive crosslinked microgels, it is possible that rare large aggregates of 
crosslinked microgels can catastrophically block blood vessels in the lung, resulting in an 





Microgels have been explored for a variety of biological applications, but their 
clinical use is limited by several factors. One of the most important of these is rapid 
clearance by the spleen or uptake by the mononuclear phagocytic system (MPS) (1). The 
initial objective for this research was to determine the effect of increasing crosslinking 
density on biodistribution and clearance time of pNIPAM-AAc microgels. This goal was 
motivated in part by studies conducted by Merkel et al. showing that an 8-fold decrease in 
the modulus of red blood cell (RBC)-mimicking hydrogel particles resulted in a 30-fold 
increase in circulation time. The softest hydrogels had an average modulus of 7.8 kPa and 
had an elimination half-life of 93.3 hours, as opposed the stiffest hydrogels, which had a 
modulus of 63.9 kPa and exhibited an elimination half-life of only 2.9 hours (96). In 
Section 3.4.1, I showed that ULC pNIPAM-AAc microgels have a Young’s modulus of 
2.71 kPa in water, which increases to 5.63 kPa in plasma. Since these ULC particles were 
softer than the hydrogel microparticles used by Merkel et al., I hypothesized that ULC 
microgels would circulate for longer than BIS-crosslinked microgels, perhaps long enough 
to enable sustained delivery of therapeutic cargo over several days. 
 Deformable microparticles of similar sizes to those investigated in this work have 
previously been shown to accumulate in the liver, spleen, and lungs, likely due to the fine 
microvasculature present in those organs (125). ULC microgels have also demonstrated 
the ability to squeeze through pores much smaller than their hydrodynamic diameter, an 
ability which decreases with crosslink density (23). I hypothesized that this unique 
deformability would allow ULC microgels to avoid accumulation in microvasculature, 
perhaps reducing the risk of organ damage from vascular occlusion. 
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 Shortly after beginning biodistribution and clearance studies, it became apparent 
that some mice that received BIS-crosslinked microgels were experiencing significant 
toxicity, specifically in their lungs. Noting that the mice who received ULC microgels did 
not show any signs of toxicity, I generated a series of hypotheses to explain how 
crosslinking with BIS could lead to pulmonary toxicity. The first was that BIS-crosslinked 
microgels raised the apparent viscosity of blood at high shear, resulting in greater stress on 
the endothelium of fine blood vessels. This hypothesis was disproven in Section 3.4.4. 
However, I noticed in static imaging of fluorescent microgels that BIS-crosslinked 
microgels seemed to form more large aggregates than ULC microgels did. I therefore 
hypothesized that BIS-crosslinked microgels form large aggregates in plasma, which 
become trapped in pulmonary microcirculation, resulting in endothelial damage an 
inflammation. Using both in vivo studies in mice and in vitro microfluidic models of 
pulmonary microcirculation, I explore this hypothesis and what it means for the future of 
microgel-based therapies. 
4.3 Materials and Methods 
4.3.1 Biodistribution and Clearance Time of pNIPAM-AAc Microgels 
pNIPAM-AAc microgels of varying crosslink density were labeled with VivoTag 
650 (PerkinElmer) through a two-step reaction: first, microgels were aminated with Tris(2-
aminoethyl)amine (Sigma Aldrich) by standard EDC/Sulfo-NHS chemistry. Next, 
aminated microgels were incubated with Vivotag in a sodium bicarbonate buffer. Unbound 
dye was removed by dialysis against deionized water with a 1000 kDa dialysis membrane 
(Spectrum Labs). Labeled microgels were then lyophilized in 10 mg batches. 
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 10 mg of labeled microgels were reconstituted in 0.5 mL of sterile saline for a final 
concentration of 20 mg/mL. 50 L was injected into 8 week old C57BL/6 mice (Jackson 
Laboratory) via tail vein injection, for a total dose of 1 mg per 20 g mouse (50 mg/kg). 
Mice were left for 5 minutes to allow microgels to circulate in the bloodstream. After 5 
minutes, 20 L of blood was drawn from the tail vein, and pipetted into heparinized tubes. 
The same process was repeated at 30 minutes, and 1, 2, 6, 12, 24, 30, 36, and 48 hours. 
Blood was diluted with 80 L PBS and pipetted into a black 96-well plate, where it was 
scanned on a near-IR scanner (LICOR). Fluorescent signal was compared against a 
standard curve of microgels diluted in PBS to calculate concentration of microgels in blood 
at each time point. To mimic the potential degradation of the fluorescent signal in vivo, the 
standard curve plate was stored in a 37 ˚C incubator and read each day to generate a new 
standard curve. 
 Following sacrifice via terminal overdose of ketamine/xylene or CO2 inhalation, 
mice were dissected and heart, kidneys, lungs, spleen, and liver were harvested. Organs 
were scanned on the near-IR LICOR scanner to assess fluorescent signal.  
4.3.2 Histology and IHC of Lung Sections 
For studies specifically investigating pulmonary toxicity of microgels, unlabeled 
microgels were used. 100 uL of a 10 mg/mL microgel suspension was injected into 8 week 
old male C57BL/6 mice (Jackson Laboratory, ME) via tail vein injection, for a total dose 
of 1 mg per 20 g mouse (50 mg/kg). Following injection, mice were monitored for signs 
of discomfort or pain until their terminal endpoint at 24 or 48 hours. Four mice were 
included per condition and timepoint. After their endpoint, mice were sacrificed by either 
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CO2 inhalation or overdose of ketamine/xylene, depending on the experiments performed 
after sacrifice. 
 Following sacrifice, mice were dissected and lungs were harvested. Organs were 
fixed in 4% paraformaldehyde overnight. Portions of each organ were saturated with 
sucrose prior to embedding with OCT in preparation for cryosectioning, or saturated with 
70% ethanol prior to embedding with paraffin. Tissue sections were generated, and selected 
sections were stained with hematoxylin and eosin (H&E) or Martius Scarlet Blue (MSB) 
stain for fibrin deposition. 
 For immunohistochemical analysis of inflammatory markers, paraffin sections 
were deparaffinized, quenched in methanol and hydrogen peroxide, antigen retrieved in 
citrate, and stained with primary antibodies for F4/80 for macrophages (BD Biosciences 
cat# 746070), Ly-6G for neutrophils (BioLegend cat# 127601), and VCAM-1 (Abcam cat# 
ab134047) and ICAM-1 (ThermoFisher cat# MA5407) on endothelial cells. Secondary 
signal was amplified with an avidin-biotin complex prior to detection with 3,3’-
diaminobenzidine (DAB, Abcam). 
4.3.3 Flow Cytometry 
Portions of lung tissue were digested in collagenase, then pushed through a fine 
mesh to break up the tissue. Red blood cells were lysed, and remaining cellular components 
were labeled with antibodies toward F4/80 (BD Biosciences cat# 746070) and Ly-6G 
(BioLegend cat# 127601) for macrophages and neutrophils, respectively, prior to analysis 
by flow cytometry at the University of Virginia flow cytometry core facility. Cell 
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infiltration was quantified by the percentage of CD45+ cells that stained positive each 
marker. 
4.3.4 Cytokine Quantification 
Following sacrifice via terminal overdose, approximately 1 mL of blood was drawn 
from mice via cardiac puncture, into heparinized tubes. Plasma was isolated via 
centrifugation. Bronchoalveolar lavage fluid (BALF) was obtained by flushing the lungs 
with 3 mL of saline with protease inhibitor. Cytokine quantification was performed via the 
Luminex mouse “megaplex” assay (ThermoFisher, MA), which measures 32 distinct 
secreted cytokines, listed in Table 4. 
Table 4: List of cytokines analyzed by the Luminex mouse “megaplex” assay.  
IL-1 IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-7 
IL-8 IL-9 IL-10 IL-12p40 IL-12p70 IL-13 IL-15 IL-17A 
CC-11  G-CSF GM-CSF IFN- IP-10 KC/GRO LIF MCP-1 
M-CSF CXCL-9 MIP-1 MIP-1 MIP-2 CCL-5 TNF VEGF 
 
4.3.5 Analysis of Static Microgel Aggregate Formation 
To assess the size of microgels formed in varying solvents, lyophilized Cy3b-
labeled or unlabeled microgels were resuspended in different solvents at a concentration of 
1 mg/mL and left to incubate for 1 hour on a rotisserie mixer at 25 ˚C. 10 uL of the 
suspension was spotted onto a coverslip blocked with bovine serum albumin to prevent 
adhesion to the substrate, and imaged with confocal microscopy. Labeled microgels were 
imaged with fluorescence and unlabeled microgels were imaged with differential 
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interference contrast. Size was calculated with the object finding tool of Volocity image 
analysis software (PerkinElmer). 
4.3.6 In Vitro Microfluidic Models of Lung Microvasculature Occlusion 
The fabrication of a polydimethylsiloxane microfluidic to mimic microvasculature 
has been discussed in previous work by the Lam group (126). Briefly, the device consists 
of branching microfluidic channels, the smallest of which are 6 m wide x 15 m tall. A 
schematic of several of the microchannels in the device is shown in Figure 13. 
 
Figure 13: Schematic of pulmonary microvasculature microfluidic device. Scale bar 100 
m. Adapted from Rosenbluth et al. (126) 
Cy3b-labeled microgels of varying crosslink density were mixed with citrated 
whole blood or plasma and perfused at a wall shear stress of 150 dyne/cm2 to recapitulate 
physiologic shear in microvasculature (105).  In certain experiments, platelets were labeled 
to visualize potential clot formation. In others, microgels were suspended in plasma instead 
of whole blood. The microfluidic device was imaged with confocal videomicroscopy, and 
occlusion of the channels over time was determined by manual review of the videos.  
4.3.7 In vitro Microfluidic Model of Endothelial Damage 
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Branching or straight channel microfluidic devices were coated with endothelial 
cells as described in previous work by the Lam group (127). Briefly, devices were coated 
with collagen and fibronectin, then human umbilical vein endothelial cells were perfused 
through the device and cultured for two to three days until confluent. Microgels were mixed 
with either media or whole blood and perfused at physiologic shear through the device. In 
certain experiments, the device was pretreated with microgels for 5 hours prior to imaging. 
In others, labeled microgels were mixed with whole blood directly before perfusing and 
imaging. Endothelial damage was assessed by disruption of the endothelial cell layer and 
staining of VCAM-1. 
4.4 Results 
4.4.1 Biodistribution and Clearance Time of pNIPAM-AAc Microgels 
Early attempts at determining the clearance time of pNIPAM-AAc microgels of 
varying crosslink density indicated that microgels injected into mice at a dose of 50 mg/kg 
reached a peak blood concentration of approximately 1.5 mg/mL a few minutes after 
injection, and displayed a half-life of about 12 hours. There was no apparent difference 
between crosslinking conditions, though this preliminary study was plagued by low sample 
number and problems with determining a robust standard curve. Once the process was 
streamlined and the study was properly powered, it became apparent that the clearance time 
of microgels in blood was much faster than previously thought. Figure 14 shows that the 
microgel signal decays rapidly, with a half-life of only 2-3 hours, and becomes 
undetectable in blood after 30 hours. 
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Figure 14: Blood clearance time of microgels of varying crosslink density injected into 
mice at 50 mg/kg. A, full 48 hour time course. B, magnified view of first 12 hours, showing 
rapid clearance in the first few hours. 
72 hours after injection, mice were sacrificed and heart, lungs, kidneys, spleen, and 
liver were scanned to check for signal from the microgels. Figure 15 shows a 
representative scan for each microgel crosslinking density. Overall, the microgel signal 
was very low at 72 hours, except in the kidneys, where microgels seem to accumulate. ULC 
microgels appeared to accumulate less than crosslinked microgels, which also were 
detectable at a low level in the lungs. 
 
Figure 15: 72 hour scans of organs dissected from mice injected with 50 mg/kg labeled 
microgels of varying crosslink density. Green is the microgel signal, and red is background 
fluorescence showing the outline of the liver. Heart and spleen were also imaged, but 
fluorescent signal was undetectable. 
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Notably, two mice from this study died prior to their terminal endpoint at 72 hours. 
One, who received 2% BIS-crosslinked microgels, died at some point between 12 and 24 
hours. The second received 8% BIS-crosslinked microgels and died at around 30 hours. In 
both cases, the mice had appeared lethargic and struggling to breathe. These mice were 
dissected, and their organ scans are shown in Figure 16. 
 
Figure 16: Organ scans of mice that died before their terminal endpoint at 72 hours.  
The microgel signal in all organs is higher than the signal at 72 hours, which is 
expected at an earlier timepoint. Kidneys still show a comparatively higher signal than 
other organs, but the most striking difference is the bright signal from the lungs not seen at 
72 hours. Taken together with the signs of breathing problems, this data motivated the 
hypothesis that crosslinked microgels may induce pulmonary toxicity to a greater degree 
than ULC microgels. The remaining data in this chapter is focused on exploring this 
hypothesis. 
4.4.2 Effects of Microgels on Lung Morphology and Histology 
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Crosslinked microgels were found to have a greater influence than ULC microgels 
on the gross morphology of lungs dissected from mice at 24 and 48 hours post injection 
(Figure 17). Mice that received ULC microgels had large, nearly white lungs with clearly 
defined lobes, similar to mice that received a saline control. By contrast, mice that received 
2% BIS- or 8% BIS-crosslinked microgels showed macroscopic signs of lung damage, 
including darkened lung tissue, compressed structure, and bleeding. These visual 
differences were apparent at 24 hours, and persisted through the 48 hour time point. 
 
Figure 17: Macroscopic images of mouse lungs dissected 24 or 48 hours after receiving 
the indicated treatment. White arrows indicate regions of darkened lung tissue, suggesting 
inflammation or tissue damage.  
In order to investigate the microscopic changes in lung tissue as a result of microgel 
exposure, lung sections were generated and stained with H&E (Figure 18). At 24 hours, 
lung structure from mice that received ULC microgels resembled that of the saline control, 
whereas mice that received 2% BIS- or 8% BIS-crosslinked microgels showed a slightly 
denser alveolar structure. This effect was more pronounced at 48 hours, especially in the 
lungs of mice who received 8% BIS-crosslinked microgels.  
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Figure 18: H&E staining of mouse lung sections 24 or 48 hours post injection with 
microgels of varying crosslink density. 20X magnification. 
Since H&E staining suggested that lung tissue was inflamed upon exposure to 
crosslinked microgels, IHC was also performed on lung sections to assay cell infiltration 
and inflammatory response. Staining for macrophages via the F4/80 receptor (Figure 19) 
showed little to no dependence on crosslinking density – even the saline control showed 
positive staining for macrophages, which may suggest resident macrophages in the lung.  
 
Figure 19: F4/80 IHC for macrophages on mouse lung sections 24 or 48 hours post 
injection with microgels of varying crosslink density. 20X magnification. 
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 Staining for neutrophils via Ly-6G also showed minimal neutrophil infiltration, 
though certain areas of lung sections from mice treated with 8% BIS-crosslinked microgels 
did stain positive for neutrophils (Figure 20). 
 
Figure 20: Ly-6G IHC for neutrophils on mouse lung sections 24 or 48 hours post injection 
with microgels of varying crosslink density. 20X magnification. Arrows show positive 
staining for neutrophils. 
Since cellular signs of inflammation were largely absent, sections were next stained 
for VCAM-1, a marker of endothelial damage. Figure 21 shows that VCAM-1 expression 
in lung endothelium is greatly enhanced in sections from lungs exposed to crosslinked 




Figure 21: IHC staining for VCAM-1 on mouse lung sections 24 or 48 hours post injection 
with microgels of varying crosslink density. 20X magnification. 
4.4.3 Inflammatory Response of Lung Tissue Exposed to Microgels 
Since injection of BIS-crosslinked microgels appears to result in denser lung tissue 
and expression of VCAM-1, I hypothesized that they may induce an inflammatory response 
in the lung. To test this hypothesis, flow cytometry was performed on homogenized lung 
tissue as well as bronchoalveolar lavage fluid (BALF) to check for infiltration of 
macrophages and neutrophils. Figure 22 shows that regardless of time point of microgel 
condition, the amount of macrophages and neutrophils in lung tissue and BALF was not 
significantly different than the saline control. This is perhaps unsurprising, as Figures 19 
and 20 showed minimal staining of these cells in lung sections as well. However, it is 
interesting to note that the 48 hour, 8% BIS condition has an exceptionally high error bar. 
This is due to one mouse in this condition showing consistently high levels of neutrophils 
and macrophages. While the overall trend is not significant, this finding perhaps points to 
the relative rarity of catastrophic toxic events from microgels. 
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Figure 22: Flow cytometry for macrophages (F4/80, A and B) and neutrophils (Ly6G, C 
and D) in partially homogenized lung tissue (A and C) and BALF (B and D). Significance 
determined by ANOVA with Tukey’s post-test, n = 4. 
Next, plasma and BALF were analyzed for levels of cytokines associated with 
endothelial damage and inflammation, namely IL-1, IL-1, TNF, and IFN. Figure 23 
shows that for the most part, there was no significant association between microgel 
treatment and inflammatory cytokine level. Figure 23B indicates that plasma IL-1 may 
be elevated in mice that received 2% BIS-crosslinked microgels at 24 hours, but the trend 
does not hold with mice that received 8% BIS-crosslinked microgels. Another interesting 
note is the high mean value and variability of plasma IFN in mice that received 8% BIS-
crosslinked microgels for 48 hours (Figure 23D). This was the same mouse that showed 
increased infiltration of neutrophils and macrophages in Figure 22B and D.  
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Figure 23: Inflammatory cytokines in plasma (A-D) and BALF (E-H) of mice injected 
with microgels of varying crosslink density. Significance determined by ANOVA with 
Tukey’s post-test, n = 4. 
4.4.4 Formation of Crosslink-dependent Microgel Aggregates 
Figure 24 shows the size of microgel aggregates that spontaneously form upon 
resuspension in various solvents. Since there was a wide range of aggregate sizes in each 
condition, the data is presented in two ways: first, a frequency distribution of small 
aggregate sizes (< 10 m2) is shown, which captures the vast majority of aggregates 
present. Next, the full set of data for each condition is shown on a logarithmic scale, to 
visualize the rare large aggregates that form in each condition. 
 In complete plasma, ULC microgels form the smallest aggregates, with a peak at 
approximately 0.5 m2. 2% BIS-crosslinked microgels are slightly larger with a peak at 
~1.5 m2. 8% BIS-crosslinked microgels have a wider distribution of small aggregate sizes, 
with many microgel aggregates ranging in size from 2 to 4 m2. When the data is presented 
as a whole, it is also apparent that BIS-crosslinked microgels form some aggregates that 
are greater than 1000 m2, whereas the largest ULC microgel aggregate is about 200 m2. 
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Since plasma is a complex fluid, it is worth considering which components contribute to 
this disparity in aggregate formation. Incubation with physiologic concentration of albumin 
alone results in a greater proportion of large (> 100 m2) aggregates across all conditions, 
though BIS-crosslinked microgels still form more of these than ULC microgels. Exposing 
microgels to only immunoglobulin results in a distribution similar to whole plasma, where 
BIS-crosslinked microgels clearly form larger aggregates than ULC microgels. When 
protein is taken out of consideration entirely, and microgels are resuspended in only PBS, 
the effect reverses – all microgels form smaller aggregates without protein, but BIS-
crosslinked microgels actually form even smaller aggregates than ULC microgels, with 
few aggregates over 10 m2. Curiously, in deionized water alone, BIS-crosslinked 
microgels once again form a greater proportion of large aggregates than ULC microgels.  
 To address concerns that aggregation was an artefact of microgel labeling, some 
experiments were repeated with unlabeled microgels and differential interference contrast 
imaging, which showed similar trends, but slightly smaller maximum aggregate size. 
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Figure 24: Formation of microgel aggregates in various solvents. The left column shows 
a frequency distribution of small (< 10 m2) aggregates, whereas the right column shows 
the full set of data on a logarithmic scale. N > 750 for each condition. 
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4.4.5 Mass Spectrometry Analysis of pNIPAM-AAc Microgel Protein Corona 
To test the hypothesis that differences in microgel aggregation arise from 
differential protein binding, the protein corona of microgels of varying crosslink density 
was analysed using protein mass spectrometry after incubation with human plasma. Figure 
25 shows the breakdown of serum proteins bound to each microgel. Unsurprisingly, the 
most abundant protein in the corona was serum albumin, which comprised from 34-40% 
of the entire protein corona of the microgels. This result corroborates work by Miceli et al. 
(49). Immunoglobulin heavy chains were the next most abundant, followed by TNF-. 
Microgels crosslinked with 2% BIS showed a slightly higher proportion of albumin in their 
protein corona, but this trend did not hold with increasing crosslinking. This suggests that 
overall, it is unlikely that microgel crosslink density significantly influences the 
composition of the protein corona. 
 
Figure 25: Proportion of serum proteins bound in the protein corona of microgels of 
varying crosslink density. 
4.4.6 pNIPAM-AAc Microgel Aggregates Can Occlude Lung Microvasculature 
Having established that pNIPAM-AAc microgels form large aggregates in a 
crosslink-dependent manner in plasma, the next goal was to test whether these aggregates 
were large and durable enough to occlude lung microvasculature. A branching microfluidic 
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device consisting of channels as small as 6 m wide by 15 m tall was used to model 
pulmonary microcirculation. Figure 26A-B shows that at a physiologic shear of 150 
dyne/cm2, microgel aggregates in human plasma become trapped in the small channels of 
the device. As expected, BIS-crosslinked microgels show more and larger aggregates that 
occlude the channels. 
 
Figure 26: Microgels in human plasma form aggregates large and durable enough to 
occlude a microfluidic model of lung microvasculature. Microgels shown in 
orange/yellow. A, devices at the start of the run. B, devices after 10 minutes of 
plasma/microgel mixture at physiologic shear (150 dyne/cm2). C, devices after an 
additional 5 minutes of 10X physiologic shear. Scale bar, 70 m. 
After 10 minutes of flow at physiologic shear, the flow rate was increased by 10-
fold to test whether the enhanced pressure could dislodge microgel aggregates and force 
them through the channels. Although a few small aggregates were moved through the 
channels at this higher flow rate, most aggregates remained lodged at the inlet of the small 
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channels (Figure 26C). This demonstrates that although ULC microgels are less likely to 
form large aggregates than BIS-crosslinked microgels, all pNIPAM-AAc microgels have 
the potential to form aggregates large and durable enough to occlude lung 
microvasculature. 
 This experiment was also performed mixing microgels with whole blood and 
perfusing through the device at physiologic shear, then measuring occlusion by manually 
recording the channels that stopped flowing blood at specific time points. These results are 
difficult to interpret, as even control blood will occlude small microfluidic channels over 
time due to non-specific clotting or aggregates of red blood cells that become lodged in the 
channels. Even so, Figure 27 shows that while there is high variability between runs, BIS-
crosslinked microgels result in a higher percentage of channels occluded by the end of a 
10 minute run. 
 
Figure 27: Occlusion of microfluidic channels with whole blood mixed with microgels of 
varying crosslink density. Data is presented as mean ± standard error, n = 6.  
4.4.7 Effect of Microgel Perfusion on Endothelialized Microfluidic 
To investigate the link between microgel aggregates and endothelial damage, 
microgels were mixed in endothelial cell growth media and perfused through an 
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endothelialized microfluidic device. Perfusion with whole blood was precluded by clotting 
upstream of the device, resulting in uneven flow and filtering of microgel aggregates. 
Damage to endothelium was determined by absence of endothelial cells along the channel, 
as well as enhanced VCAM-1 expression on endothelial cells. Figure 28 shows that 
regardless of microgel treatment, the endothelial cell layer remained confluent and VCAM-
1 expression was similar between all conditions. However, this may be due to the 
comparatively large size of the channels in relation to the previous microfluidic. Since 
smaller channels cannot be endothelialized, these channels were 100 m2 tall by 100 m2 
wide. 
 
Figure 28: Endothelialized cell device after 5 hours perfusion of growth media plus 
microgels of varying crosslink density. Top, full fluorescent signal with endothelial cell 
nuclei in blue, VCAM-1 in green. Bottom, brightened version of VCAM-1 signal. 






4.5.1 Crosslink-dependent pNIPAM-AAc Microgel Aggregate Formation 
Microgel aggregate formation is a complex process with multiple influencing 
factors. In whole plasma, all microgels form aggregates, but 8% BIS-crosslinked microgels 
form a broader distribution of “small” aggregates (< 10 m2) than ULC or 2% BIS-
crosslinked aggregates. Both varieties of BIS-crosslinked microgels form a small number 
of massive aggregates in excess of 1000 m2, whereas all ULC aggregates were smaller 
than 200 m2. To put this data in the context of pulmonary microcirculation, it is useful to 
note that the average capillary diameter in the human lung is 6.3 m, corresponding to a 
cross sectional area of about 31 m2 (128). Thus, any aggregate in excess of this size has 
the potential to occlude lung microvasculature. When suspended in PBS alone, without 
protein and other biomolecules, the small aggregate trend remained the same, but few very 
large aggregates were formed. In fact, ULC microgels seemed to form more large 
aggregates, up to ~ 100 m2, than BIS-crosslinked microgels.  To ascertain which plasma 
components could be responsible for enhanced, crosslink-specific aggregation, microgels 
were suspended in either albumin or immunoglobulin alone, each at their approximate 
physiologic concentration. Albumin resulted in large aggregate formation across all 
microgel varieties, though BIS-crosslinked microgels still a greater number of aggregates 
greater than 1000 m2. Immunoglobulin resulted in a similar profile to whole plasma, 
where BIS-crosslinked microgels formed larger aggregates than ULC microgels. Notably, 
8% BIS microgels suspended in immunoglobulin formed even more larger aggregates than 
8% BIS microgels in plasma. These results agree with previous work by Müller et al. 
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showing that albumin and immunoglobulins in the protein corona contribute to 
nanoparticle aggregation in plasma (39). Interestingly, microgels in deionized water also 
show a similar aggregation profile to those in whole plasma.  
How does it make sense that PBS is the only condition without large aggregate 
formation? A potential explanation is that aggregates can result from multiple distinct 
forces. Looking first at the two conditions without protein, it is apparent that in deionized 
water, all microgels form small aggregates (< 10 m2) that are approximately the same 
size, whereas in PBS, BIS-crosslinked microgels form small aggregates with a broader 
distribution of sizes. This suggests that there is either an electrostatic component stabilizing 
small microgel aggregates in water that is shielded when microgels are suspended in PBS, 
or that microgel deswelling in PBS promotes aggregation. Section 3.4.3 demonstrated that 
the swelling behavior of the microgels is very similar, regardless of crosslink density, so it 
is unlikely that differences in swelling are behind this response. Since all microgels carry 
a net negative charge due to AAc, it is possible that the electrostatic explanation is valid 
for small aggregate sizes. The particularly large aggregates in deionized water may be due 
to hydrophobic interactions between the dye conjugated to microgels, though it is unclear 
why BIS-crosslinked microgels still form more large aggregates. When protein is 
introduced, it is clear that albumin promotes aggregation to a greater extent than 
immunoglobulin. From that perspective, it is possible that BIS-crosslinked microgels bind 
a greater proportion of albumin that do ULC microgels.  
Miceli et al. found slightly different results regarding pNIPAM-based microgel 
protein binding an aggregate formation, though the microgels in that study were 
copolymerized with dendritic polyglycerol (dPG). Their results point to immunoglobulin 
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binding as a source of reversible aggregation of microgels, and note that immunoglobulin 
bound to a greater extent when the microgels were partially collapsed at physiologic 
temperature (49). This perhaps suggests that the most important source of microgel 
aggregation is hydrophobic protein binding. From this perspective, it is possible that BIS-
crosslinked microgels are more hydrophobic than ULC microgels regardless of swelling 
state, making them more prone to aggregation. 
It should be noted that all of the data shown for static microgel aggregate formation 
were from microgels that had been pre-labeled with a Cy3b-NHS ester dye. The labeling 
procedure is two-step: first, the AAc sites on microgels were aminated with Tris(2-
aminoethyl)amine, followed by incubation with Cy3b-NHS ester. In the process, most of 
the net negative charge of the microgels was likely lost. This could have the effect of 
lowering the VPTT of the microgels, making them more likely to collapse into their 
hydrophobic states, perhaps promoting aggregation. To address this concern, some studies 
were performed with unlabeled microgels, using differential interference contrast imaging. 
Although the maximum aggregate size was smaller in these studies, there was still evidence 
that crosslinked microgels aggregated to a greater size than ULC microgels. 
4.5.2 Interpretation of Biodistribution and Clearance Time 
The blood clearance time of pNIPAM-AAc microgels was shown to be much more 
rapid than originally thought. Most of the microgel signal in blood had decayed by 12 
hours, and it was undetectable after 30 hours. Initially, I hypothesized that ULC microgels, 
by virtue of their lower elastic modulus, would stay in circulation for longer than BIS-
crosslinked microgels, following work by Merkel et al. (96). However, there are several 
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key differences between RBC-mimicking particles in the Merkel study and the pNIPAM-
AAc microgels explored here. For one, the hydrogels in the Merkel study were designed 
to be discs with 5.2-5.9 m diameters and 1.22-1.54 m tall, recapitulating the shape of 
native RBCs. Not only do large particles stay in circulation for longer than smaller ones, 
but non-spherical particles are known to have a longer circulation time than spherical ones 
(95). Since the pNIPAM-AAc microgels investigated here are approximately 1 m in 
diameter, and universally spherical, it stands to reason that their circulation time would be 
much shorter, and any differences between crosslinking conditions would be negligible. 
Furthermore, the difference in modulus between the stiffest and softest particles in 
Merkel’s study was about 8-fold, as opposed to an approximate 4-fold difference between 
ULC and 8% BIS-crosslinked microgels.  
 Although the particles did not last long in blood, there was evidence of a high 
microgel signal in lungs and kidneys at 24 hours, with signal remaining in the kidneys for 
up to 72 hours. Considering the size of the microgel aggregates discussed in Section 4.5.1, 
a more apt comparison for biodistribution may be a study of purposely aggregated PEG 
microgels with an average aggregate diameter of 30 m. Deshmukh and colleagues found 
that these aggregates accumulated in the lung within 30 minutes, and persisted for 48 hours 
before being enzymatically degraded to their principal components and eliminated by renal 
filtration (106). Putting these results in the context of the findings presented here, a two 
phase model of pNIPAM-AAc microgel biodistribution can be considered: first, individual 
microgels are rapidly cleared within 12-24 hours. Next, microgel aggregates accumulate in 
the lungs and kidneys, until they are degraded over the course of 3 to 4 days. 
 84 
4.5.3 Pulmonary Toxicity of pNIPAM-AAc Microgel Aggregates 
The microfluidic experiments demonstrate that microgel aggregates are large and 
durable enough to occlude lung microvasculature, even at supraphysiologic flow rates. As 
with static experiments, BIS-crosslinked microgels formed more large aggregates that 
became trapped in the microchannels. While there was little evidence of endothelial 
damage in the endothelialized microfluidic device, there are a few potential explanations 
for this. For one, the channels of the endothelialized device were much larger than the 
device used to model pulmonary microvasculature. Whereas the pulmonary device had a 
smallest channel size of 6 m wide by 15 m tall (90 m2 cross-sectional area), the 
endothelialized device had a channel size of 100 m wide by 100 m wall (10,000 m2 
cross-sectional area). Figure 24 demonstrates that even in BIS-crosslinked conditions, no 
aggregates approached this size, so it’s possible that no aggregates made contact with the 
endothelial wall. Furthermore, since upstream clotting prevented running these 
experiments in whole blood, most microgels were probably pushed away from the 
endothelialized walls of the channel by lift velocity from the shear gradient, known as the 
Fahraeus-Lindquist effect (115).  
While discrete instances of toxicity were observed in vivo, the overall inflammatory 
response of microgels was not greater than that of saline controls. This is perhaps 
unsurprising; Miceli et al. found that pNIPAM-based microgels form a dysopsonin-rich 
protein corona, which would reduce their likelihood of being recognized  and phagocytosed 
by immune cells such as macrophages and neutrophils (49).  
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 Instead, an alternate explanation for toxicity emerges. Instead of BIS-crosslinked 
microgel aggregates causing incremental damage to pulmonary endothelium, the instances 
of toxicity could be explained by the rare, truly massive microgel aggregates that form 
from BIS-crosslinked microgels. Instead of inflammation, toxicity like this could be more 
akin to a single catastrophic event such as a pulmonary embolism. It may not happen in 
every mouse (or human) injected with BIS-crosslinked microgels, but the risk for an 
especially large aggregate is higher for those injected with BIS-crosslinked microgels than 
for those injected with ULC microgels. Since ULCs do not form these massive aggregates, 
they are not as high of a toxicity risk.  
 From a contrarian standpoint, aggregate formation may be a useful behavior. All 
microgel crosslinking conditions form aggregates that are at least temporarily trapped in 
lung and kidney microvasculature. This could be exploited by using microgels to 
specifically deliver therapeutic cargo to lungs or kidneys, without the need for additional 
targeting moieties. For example, antifibrotic medications such as nintedanib (brand name 
Ofev or Vargatef) could be loaded into microgels and injected into patients with idiopathic 
pulmonary fibrosis, limiting off-target effects. The challenge would be ensuring that 
aggregate size is stabilized, perhaps by copolymerizing hydrophilic monomers into the 
microgel particle. 
4.6 Conclusion 
The work presented here adds to our understanding of pNIPAM-based microgel 
pharmacokinetics, which is critical to advancing microgel technology to the clinical space. 
I find here that regardless of crosslinking density, most pNIPAM-AAc microgels are 
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cleared from blood within 12 hours, but accumulate in tissues such as lungs and kidneys. 
Furthermore, I demonstrate that crosslinked microgels more readily form large aggregates 
in blood that occlude lung microvasculature and have the potential to cause fatal toxic 
events. It is likely that aggregation is driven by hydrophobic forces; thus, this research 
underscores that microgels intended to be used in vivo should be composed of polymers 
that remain hydrophilic in physiologic conditions. 
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CHAPTER 5. OVERALL CONCLUSIONS AND FUTURE 
DIRECTIONS 
Over the past two decades, there has been a massive surge in research involving 
microgels for biomedical applications. Because of their tunability, ease of synthesis, and 
ability to hold large amounts of therapeutic cargo relative to their size, microgels are an 
ideal platform for drug delivery, imaging, and biosensors. Yet despite promising 
preliminary data, only a couple of microgel-based therapies have reached clinical trials. A 
major obstacle for clinical translation of microgels is their rapid clearance and toxic or off-
target effects in vivo, which motivated this work.  
 The work presented here demonstrated that crosslinking predictably increases the 
Young’s, shear, and bulk moduli of pNIPAM-AAc microgels. Additionally, this research 
shows, for the first time, the effect of exposure to blood plasma on the mechanical 
properties of individual microgels. While plasma binding stiffens ULC and 8% BIS-
crosslinked microgels, it has minimal effect on the stiffness of 2% BIS-crosslinked 
microgels, which was unexpected. Furthermore, these studies pioneered the use of multiple 
AFM nanoindentation techniques to tease out the shear and bulk moduli of pNIPAM-AAc 
microgels, revealing that bulk modulus is lower than shear modulus for all microgels 
studied, regardless of solvent. This indicates that it requires less force to compress 
microgels than to shear them, which may be useful in predicting their behavior in blood 
flow. 
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 Beyond single-microgel mechanical analysis, this thesis also investigated how 
crosslinking affects the bulk behavior of microgels in whole blood. At common therapeutic 
doses, microgels do not affect the apparent viscosity of blood, suggesting that they do not 
induce significant hemolysis or affect RBC deformability and aggregation. One surprising 
result was that microgels do not readily marginate to the walls of microchannels, regardless 
of crosslinking density. Based on models of platelet margination and reports of leukocyte 
softening leading to demargination (115, 121), I had originally hypothesized that BIS-
crosslinked microgels would marginate more effectively than ULC microgels. The finding 
that none of the microgels marginated effectively may be because even the stiffest are not 
sufficiently stiffer than RBCs. Those designing microgels for therapeutic delivery to 
vasculature may therefore aim to generate even stiffer microgels to enable margination and 
higher effective doses at the vessel wall.  
 An obvious extension of this work is to investigate the mechanical behaviors of 
other varieties of microgels, such as those formed from PEG. It has been shown that 
different polymers bind different proteins in plasma (49), so it stands to reason that their 
mechanical response to plasma exposure may differ as well. Furthermore, microgels 
synthesized with hollow cores, such as those developed by the Brown group (5) will likely 
have drastically different mechanical properties and swelling kinetics. The experiments 
and analyses outlined in this work can serve as a toolkit for interrogating the mechanics of 
any type of microgel particle. 
 Toward the goal of characterizing pNIPAM-AAc microgel behavior in vivo, I 
hypothesized that ULC microgels would exhibit a longer circulation time than BIS-
crosslinked microgels, based on work by Merkel et al. that demonstrated longer half-lives 
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with hydrogels of lower modulus (96). However, my results indicated that regardless of 
crosslink density, pNIPAM-AAc microgels display a very short circulation time in blood, 
with a half-life on the order of a few hours, and are completely undetectable in blood after 
30 hours. Interestingly, the microgels (and especially BIS-crosslinked microgels) seem to 
accumulate in lungs, and especially kidneys, for up to several days after injection. A key 
difference between these microgels and the hydrogels developed in the Merkel study is 
size: whereas all microgels in this study had a diameter of approximately 1 m, hydrogels 
in the Merkel study were designed to mimic RBCs, which are considerably larger and 
discoid-shaped. To extend circulation time of pNIPAM-AAc microgles, a straightforward 
continuation of the work in this thesis could be to test so-called “giant” ULC (GULC) 
microgels developed by the Lyon group, which are about 8 m in diameter (23). 
 A critical aspect to in vivo clearance of biomaterials is their likelihood of being 
internalized by components of the mononuclear phagocytic system (MPS). Previous work 
has shown that both the microgel polymer core and the components of its protein corona 
in vivo influence the degree of uptake by the MPS (39, 40). Furthermore, it has been shown 
that nanoparticle stiffness influences whether particles are internalized by 
micropinocytosis or clathrin-mediated endocytosis (28). Since the work presented here 
demonstrates that crosslink density  clearly influences microgel stiffness in vivo, and that 
crosslinking may cause microgels to bind plasma proteins differently, future work on 
pNIPAM-AAc microgels should explore the effect of crosslinking on MPS uptake. 
 One of the most striking observations of this work was the effect of crosslinking 
density on microgel aggregation. Results presented here point to hydrophobic forces as a 
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primary driver of aggregation, though a critical question remains: Is aggregation caused by 
hydrophobic interactions between pNIPAM chains, or binding between corona proteins 
that differentially bind microgels through hydrophobic interactions? On one hand, the data 
in this thesis agrees with previous literature on the influence of plasma proteins on microgel 
aggregation. Miceli et al. found that hydrophobic collapse of pNIPAM-based microgels led 
to immunoglobulin binding, and subsequent aggregation (49), which agrees with data in 
Figure 24. This data also suggests that albumin may promote aggregation more potently 
than immunoglobulin. Thus, one could hypothesize that the corona of BIS-crosslinked 
microgels contains a greater proportion of albumin than that of ULC microgels. However, 
Figure 25 demonstrates that if BIS-crosslinked microgels bind a greater proportion of 
albumin, the effect size is minimal. Beyond the biochemical composition of the protein 
corona, it may be also be useful to evaluate the morphology of microgels of varying 
crosslink density after corona formation using scanning electron microscopy. 
 However, based on the results in deionized water, it is apparent that protein corona 
alone cannot fully explain the crosslink-dependent aggregation behavior. It is possible that 
BIS-crosslinking confers enhanced hydrophobicity to pNIPAM-AAc microgels, leading to 
greater aggregation. Future studies of this behavior should include pNIPAM-AAc 
microgels that have been copolymerized with a stably hydrophilic monomer such as PEG 
to elucidate the effects of hydrophobicity on microgel aggregation in vivo.  
 Microgel aggregates were found to be large and durable enough to occlude lung 
microvasculature as modeled by a microfluidic device, though there are limitations to this 
experiment. For one, results in whole blood were complicated by upstream clotting in the 
device, leading to inconsistent flow and occasional large platelet aggregates that were not 
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associated with the microgel treatment. Additionally, the microchannels in the device 
recapitulating lung microvasculature were too small to be endothelialized with current 
protocols, which precluded assays of endothelial damage in a relevant model. Ongoing 
improvements in fabricating and endothelializing microfluidic devices for blood flow will 
allow for more accurate models of endothelial damage in the lung.  
Surprisingly, the tendency of BIS-crosslinked microgels to form large aggregates 
in plasma did not lead to broadly enhanced inflammation in the mice that received them. 
There was some evidence of localized inflammation and tissue damage in lung sections, 
but this did not translate to reliably elevated cytokine expression or cell infiltration. I 
postulate here that the observed toxicity in certain mice may reflect a catastrophic event 
from especially large microgels, akin to a pulmonary embolism. While not every dose of 
microgels might result in such large aggregates, the risk is higher for BIS-crosslinked 
microgels. To explore this possibility further, a much larger animal study would be required 
in order to obtain sufficient statistical power.  
Instead of viewing aggregation as something to be avoided, it is intriguing to 
imagine exploiting this behavior for therapeutic delivery. This work has shown that 
pNIPAM-AAc microgels of all types accumulate in the lungs and kidneys, apparently 
without causing large-scale inflammation. If the maximum aggregate size can be stabilized 
to a point where it no longer poses the threat of catastrophic occlusion, perhaps by 
copolymerizing especially hydrophilic polymers such as PEG, microgel aggregates could 
be an ideal vehicle for delivering molecules to lungs or kidneys, without the need for 
additional targeting moieties. This strategy is not without precedent; Deshmukh et al. 
showed that stabilized aggregates of PEG microgels accumulate in the lungs without toxic 
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side effects and can be utilized for delivery of therapeutic cargo (106). Since pNIPAM-
AAc microgels spontaneously form aggregates in plasma, future development of a similar 
strategy would need to focus on optimizing aggregate size through crosslinking and co-
polymer composition. 
In summary, this thesis contributes to our knowledge about the mechanical 
responses of pNIPAM-AAc microgels, and how they respond to physiologic conditions. 
Furthermore, the methods outlined in this work give future researchers a reliable toolbox 
for interrogating the mechanical properties of a wide range of microgel constructs. Finally, 
this work demonstrates that crosslinking pNIPAM-AAc microgels with BIS leads to a 
greater propensity for aggregation, with potential toxic effects in vivo. While this thesis 
may be read as a cautionary tale for those designing similar microgel systems, I also present 
ideas for avoiding truly catastrophic aggregation-related events, and offer the potential for 
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